



European
Crohn's and Colitis
Organisation

Vienna
Austria

Inflammatory Bowel Diseases

Pocket Guide



15th Congress of ECCO
Reed Messe Wien
February 12-15, 2020

www.ecco-ibd.eu

Opening hours

Cloakroom

Wednesday, February 12, 2020	07:00 - 22:00
Thursday, February 13, 2020	07:00 - 21:15
Friday, February 14, 2020	06:45 - 20:00
Saturday, February 15, 2020	08:00 - 14:00

ECCO Congress Office and Registration Desk

Wednesday, February 12, 2020	07:00 - 19:00
Thursday, February 13, 2020	07:00 - 19:00
Friday, February 14, 2020	07:00 - 19:00
Saturday, February 15, 2020	08:00 - 13:00

Industry and Poster Exhibition

Thursday, February 13, 2020	10:30 - 18:00
Friday, February 14, 2020	08:00 - 18:00
Saturday, February 15, 2020	08:00 - 13:00

Members' Lounge (exclusive for ECCO Members)

Thursday, February 13, 2020	10:30 - 18:00
Friday, February 14, 2020	08:00 - 18:00
Saturday, February 15, 2020	08:00 - 13:00

Speakers' Centre

Wednesday, February 12, 2020	07:00 - 18:00
Thursday, February 13, 2020	07:00 - 19:30
Friday, February 14, 2020	06:45 - 19:30
Saturday, February 15, 2020	08:00 - 13:00

For latest updates, please scan this QR Code and check out the changes page on the ECCO Website.





European
Crohn's and Colitis
Organisation

ECCO IBD APP



The World of ECCO in your pocket

Features and Benefits:

- Listen to Audio Podcasts and watch Talking Heads on the go
- Discover the new e-Guide
- Access ECCO News at any time
- Find more ECCO Initiatives at one glance
- Stay up-to-date in the IBD World
- Explore the ECCO'20 Congress

Available in App Stores free of charge:



"IBD beyond 2020"

Thursday, February 13, 2020

Scientific programme day by day (as of January 15, 2020)

Plenary Hall, Hall D, Reed Messe Wien

11:00 - 12:00	Industry Sponsored Satellite Symposia 1a (Plenary Hall), 1b (Parallel Hall) & 1c (Lehar 1-3)
12:15 - 12:20	1: Welcome H. Tilg, Innsbruck, Austria
12:20 - 12:30	2: Opening S. Danese, Milan, Italy
12:30 - 14:00	Scientific Session 1: Hot debates in IBD W. Reinisch, Vienna, Austria N. Yassin, Birmingham, United Kingdom
12:30 - 12:50	3: Is there still a place for anti-TNF in 2020? T. Ahmad, Exeter, United Kingdom J. Lindsay, London, United Kingdom
12:50 - 13:00	4: OP01: Higher versus standard adalimumab maintenance regimens in patients with Moderately to Severely Active Ulcerative Colitis: Results from the SERENE-UC maintenance study J. Colombel, New York, United States
13:00 - 13:20	5: Early Crohn's: Surgery first and early medicine later? A. Armuzzi, Rome, Italy A. D'Hoore, Leuven, Belgium
13:20 - 13:30	6: OP02: Impact of therapeutic strategies on intestinal resection rate in paediatric Inflammatory Bowel Diseases: A population-based cohort study over a 24-year period (1988-2011) D. Ley, Lille, France
13:30 - 13:40	7: OP03: Reduced need for surgery and medical therapy after early ileocaecal resection for Crohn's Disease: Long-term follow up of the LIRIC trial T. Stevens, Amsterdam, The Netherlands
13:40 - 14:00	8: Monitoring IBD: Can we abandon endoscopy? C. Hedin, Stockholm, Sweden E. Louis, Liège, Belgium
14:00 - 14:30	Coffee break

OP = Oral presentation – Best abstracts

14:30 - 16:00	Scientific Session 2: When location makes the difference J. Burisch, Hvidovre, Denmark F. Magro Dias, Porto, Portugal
14:30 - 14:50	9: Colonic versus small bowel CD: Same mechanism – same treatment? B. Siegmund, Berlin, Germany
14:50 - 15:00	10: OP04: Long-term outcomes after ileocolonic resection in Crohn's Disease according to severity of early endoscopic recurrence N. Hammoudi, Paris, France
15:00 - 15:20	11: Proctitis – a lonely disease? T. Raine, Cambridge, United Kingdom
15:20 - 15:30	12: OP05: Validation of the Lémann Index in Crohn's Disease B. Pariente, Lille, France
15:30 - 15:40	13: OP06: Comparison between Crohn and celiac diseases small intestine transcriptomics and microbial data define similarities and divergent pathways linked to pathogenesis Y. Haberman Ziv, Tel Aviv, Israel
15:40 - 16:00	14: Surgery for enteric IBD – does location matter? C. Buskens, Amsterdam, The Netherlands
16:00 - 17:20	Scientific Session 3: Reducing the burden of IBD N. Ding, Fitzroy, Australia J. Gisbert, Madrid, Spain
16:00 - 16:20	15: Reducing infections with biologics and immune-modulators S. Ben-Horin, Ramat Gan, Israel
16:20 - 16:40	16: Reducing neoplastic complications of therapy L. Beaugerie, Paris, France
16:40 - 16:50	17: OP07: The epidemiology of Inflammatory Bowel Diseases among immigrants to Denmark: A population-based cohort study M. Agrawal, New York, United States
16:50 - 17:00	18: OP08: Inflammatory Bowel Disease and risk of small bowel cancer: A binational population-based cohort study from Denmark and Sweden J. Axelrad, New York, United States
17:00 - 17:20	19: Reducing postoperative complications K. Gecse, Amsterdam, The Netherlands
17:30 - 18:30	Digital Oral Presentations (Sessions 1-5) See pg. 14
18:45 - 19:45	Industry Sponsored Satellite Symposia 2a (Plenary Hall), 2b (Parallel Hall) & 2c (Lehar 1-3)

OP = Oral presentation – Best abstracts

Friday, February 14, 2020

Scientific programme day by day (as of January 15, 2020)

Plenary Hall, Hall D, Reed Messe Wien

07:15 - 08:15	Industry Sponsored Morning Satellite Symposia 3b (Parallel Hall) & 3c (Lehar 1-3)
08:30 - 10:30	Scientific Session 4: IBD out of the gut L. de Ridder, Rotterdam, The Netherlands G. Mantzaris, Athens, Greece
08:30 - 08:50	20: Orofacial Crohn's S. Sebastian, Hull, United Kingdom
08:50 - 09:00	21: OP09: Immunomodulatory mechanisms of faecal microbiota transplantation is associated with clinical response in Ulcerative Colitis – early results from STOP-Colitis M. Quraishi, Birmingham, United Kingdom
09:00 - 09:10	22: OP10: IgA coating of intestinal microbiota is associated with Inflammatory Bowel Disease in twin pairs discordant for Inflammatory Bowel Disease E. Brand, Utrecht, The Netherlands
09:10 - 09:20	23: OP11: Exposure to an inflammatory mix re-induces inflammation in organoids of Ulcerative Colitis patients, independent of the inflammatory state of the tissue of origin K. Arnauts, Leuven, Belgium
09:20 - 09:40	24: Perianal disease or hidradenitis suppurativa – does it matter? W. Reinisch, Vienna, Austria H. Maier, Vienna, Austria
09:40 - 09:50	25: OP12: The incidence and disease course of Perianal Crohn's Disease – A Danish nationwide cohort study M. Wewer, Copenhagen, Denmark
09:50 - 10:00	26: OP13: Glyco-fingerprint as a relevant risk factor on colitis-associated cancer A. Dias, Porto, Portugal
10:00 - 10:10	27: OP14: Risk of colorectal cancer diagnosis and colorectal cancer mortality in Crohn's Disease: A Scandinavian population-based cohort study O. Olen, Stockholm, Sweden
10:10 - 10:30	28: Managing fatigue in IBD A. Dignass, Frankfurt, Germany
10:30 - 11:00	Coffee break

OP = Oral presentation – Best abstracts

11:00 - 12:30	Scientific Session 5: Cartels in IBD – Part 1 I. Dotan, Petah Tikva, Israel P. Irving, London, United Kingdom
11:00 - 11:20	29: IBD genetics consortium S. Vermeire, Leuven, Belgium
11:20 - 11:30	30: OP15: Multi-omic data integration with network analysis reveal underlying molecular mechanisms driving Crohn's Disease heterogeneity B. Verstockt, Leuven, Belgium
11:30 - 11:50	31: Prevention initiatives J. Colombel, New York, United States
11:50 - 12:00	32: OP16: Influence of early life factors on the development of intestinal microbiota of infants born to mothers with and without IBD J. Guedelha Sabino, Leuven, Belgium
12:00 - 12:10	33: OP17: Protein intakes and risk of Inflammatory Bowel Disease in the European Prospective Investigation into Cancer and Nutrition cohort (EPIC-IBD) C. Dong, Saint-Mandé, France
12:10 - 12:20	34: OP18: Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn's Disease: The SuPREMe-CD Study G. Luglio, San Prisco, Italy
12:20 - 12:30	35: OP19: Perinatal factors do not affect paediatric Inflammatory Bowel Disease risk: A Scottish nationwide cohort study using administrative health data 1981-2017 C. Burgess, Edinburgh, United Kingdom
12:30 - 13:30	Break / Guided Poster Session (Hall C) See pg. 16
12:40 - 13:20	Industry Sponsored Lunch Satellite Symposia LS1 (Plenary Hall), LS2 (Parallel Hall), LS3 (Lehar 1-3) & LS4 (Strauss 1-2)



European
Crohn's and Colitis
Organisation

Why submit your research to JCC?



Prompt and professional peer review

JCC publishes research that has undergone rigorous peer review, including an initial screening by one of the Editors and recommendations by independent reviewers. The average time from submission to first decision is two weeks.

High Impact Factor

With its 2018 Impact Factor, which now stands at 7.827, JCC ranks highly among gastroenterology and hepatology journals.

Scan and visit

www.ecco-ibd.eu



Friday, February 14, 2020, cont.

Scientific programme day by day (as of January 15, 2020)

Plenary Hall, Hall D, Reed Messe Wien

13:30 - 15:00	Scientific Session 6: Cartels in IBD – Part 2 F. Baert, Roeselare, Belgium U. Kopylov, Tel Aviv, Israel
13:30 - 13:50	36: Microbiome consortium J. Raes, Leuven, Belgium
13:50 - 14:00	37: OP20: The gut microbiota during biological therapy for Inflammatory Bowel Disease C. Caenepeel, Kessel, Belgium
14:00 - 14:20	38: TDM consortium K. Papamichail, Bosten, United States
14:20 - 14:30	39: OP21: Positivity thresholds of a total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service N. Kennedy, Exeter, United Kingdom
14:30 - 14:40	40: OP22: Crohn's Disease exclusion diet reduces bacterial dysbiosis towards healthy controls in paediatric Crohn's Disease J. Van Limbergen, Amsterdam, The Netherlands
14:40 - 15:00	41: ECCO Quality Standards of Care G. Fiorino, Rozzano, Italy
15:00 - 15:30	Coffee break
EITHER:	
15:30 - 16:10	Scientific Session 7: Milestones in clinical care (Plenary Hall, Hall D, Reed Messe Wien) J. Halfvarson, Örebro, Sweden S. Jäghult, Stockholm, Sweden
15:30 - 15:37	42: I-CARE L. Peyrin-Biroulet, Vandoeuvre-Lès-Nancy, France
15:37 - 15:47	43: OP23: Efficacy and safety of vedolizumab SC in patients with Moderately to Severely active Crohn's Disease: Results of the VISIBLE 2 study S. Vermeire, Leuven, Belgium
15:47 - 15:54	44: UR-CARE F. Baert, Roeselare, Belgium
15:54 - 16:04	45: OP24: A novel subcutaneous infliximab (CT-P13): 1-year results including switching results from intravenous infliximab (CT-P13) in patients with active Crohn's Disease and Ulcerative Colitis S. Ben-Horin, Ramat Gan, Israel
16:04 - 16:10	46: IBD Nurse Education Programme K. Kemp, Manchester, United Kingdom

OP = Oral presentation – Best abstracts

Scientific programme day by day

16:10 - 17:10	Scientific Session 8: IBD Horizons (Plenary Hall, Hall D, Reed Messe Wien) G. D'Haens, Amsterdam, The Netherlands S. Schreiber, Kiel, Germany
16:10 - 16:20	47: OP25: Biologics before surgery for IBD – Are they associated with post-operative infectious outcomes? Results from the National Surgical Quality Improvement Program Inflammatory Bowel Disease Collaborative S. Holubar, Cleveland, United States
16:20 - 16:30	48: OP26: The first real-life multicentre prospective validation study of the electronic chromoendoscopy score (Paddington International Virtual ChromoendoScopy ScOre) and its outcome in Ulcerative Colitis M. Iacucci, Birmingham, United Kingdom
16:30 - 16:40	49: OP27: Long-term safety and efficacy of risankizumab treatment in patients with Crohn's Disease: Final results from the Phase 2 open-label extension study M. Ferrante, Leuven, Belgium
16:40 - 16:50	50: OP28: Gene expression (GE) values in a phase 2 trial of mirikizumab in Ulcerative Colitis (UC) correlate better with histopathology (HP) than endoscopy (EN) and Mayo scores K. Gottlieb, Indianapolis, United States
16:50 - 17:00	51: OP29: Tofacitinib in Ulcerative Colitis: Real world evidence from Eneida Registry M. Chaparro, Madrid, Spain
17:00 - 17:10	52: OP30: The interplay of microbiome dysbiosis and immune system deregulation in patients with Crohn's Disease N. Seyed Tabib, Leuven, Belgium

OP = Oral presentation – Best abstracts

Friday, February 14, 2020, cont.

Scientific programme day by day (as of January 15, 2020)

Parallel Hall, Hall C, Reed Messe Wien

OR:

15:30 - 17:10	<i>Scientific Session 9: Basic Science: Big Data research</i> (Parallel Hall, Hall C, Reed Messe Wien) S. Zeissig, Dresden, Germany L. Egan, Galway, Ireland
15:30 - 15:50	<i>53: Pits and pearls of Big Data in scientific research: Computational analysis, deconvolution, machine learning and more</i> A. Franke, Kiel, Germany
15:50 - 16:00	<i>54: OP31: Meta-omics reveals microbiome driven proteolysis as a contributing factor to severity of Ulcerative Colitis disease activity</i> P. Dulai, San Diego, United States
16:00 - 16:10	<i>55: OP32: Mincle signaling promotes intestinal mucosal inflammation through induction of macrophage pyroptosis and neutrophil chemotaxis in Crohn's Disease</i> W. Gong, Nanjing, China
16:10 - 16:30	<i>56: Integrating multi-omics in IBD</i> A. Kaser, Cambridge, United Kingdom
16:30 - 16:40	<i>57: OP33: Multi-omics analysis reveals specific bio-geographical and functional characteristics in Inflammatory Bowel Disease intestinal mucosa</i> N. Maimon, Haifa, Israel
16:40 - 16:50	<i>58: OP34: Whole blood profiling of T-cell derived miRNA allows the development of prognostic models in Inflammatory Bowel Disease</i> R. Kalla, Edinburgh, United Kingdom
16:50 - 17:10	<i>59: How Big Data changes medicine: Concrete examples for translating Big Data into daily clinical practice</i> Y. Chowers, Haifa, Israel
17:25 - 18:25	<i>Digital Oral Presentations (Sessions 6-10)</i> See pg. 15
18:40 - 19:40	<i>Industry Sponsored Satellite Symposia 4b (Parallel Hall), 4c (Lehar 1-3) & 4d (Strauss 1-2)</i>

OP = Oral presentation – Best abstracts

Saturday, February 15, 2020

Scientific programme day by day (as of January 15, 2020)

Plenary Hall, Hall D, Reed Messe Wien

08:30 - 10:20	<i>Scientific Session 10: Multidisciplinary cases</i> D. Turner, Jerusalem, Israel M. Ferrante, Leuven, Belgium P. Michetti, Lausanne, Switzerland Y. Panis, Clichy, France
08:30 - 08:40	<i>60: GRADE-ing Guidelines: ECCO CD Treatment</i> J. Torres, Loures, Portugal M. Adamina, Winterthur, Switzerland
08:40 - 08:50	<i>61: ECCO ESPGHAN Guideline Pitch on Paediatric CD (update)</i> F. Ruemmele, Paris, France P. Van Rheenen, Groningen, The Netherlands
08:50 - 09:00	<i>62: OP35: Treatment outcomes of Inflammatory Bowel Disease in the biological era – A nationwide retrospective cohort study in three Nordic countries: Results from the TRINordic study</i> M. Zhao, Hvidovre, Denmark
09:00 - 09:20	<i>63: Clinical Case: Medical CD</i> R. Panaccione, Calgary, Canada
09:20 - 09:30	<i>64: OP36: Investigating the role of bioactives produced by gut bacteria to modulate immune response in Inflammatory Bowel Disease</i> R. Giri, Brisbane, Australia
09:30 - 09:50	<i>65: Clinical Case: Surgical CD</i> P. Kotze, Curitiba, Brazil
09:50 - 10:00	<i>66: OP37: Fibrogenesis in chronic DSS colitis is driven by an innate lymphoid cell-independent innate immune response</i> B. Creyngs, Leuven, Belgium
10:00 - 10:20	<i>67: Clinical Case: Paediatric CD</i> D. Turner, Jerusalem, Israel
10:20 - 10:50	<i>Coffee break</i>

OP = Oral presentation – Best abstracts

10:50 - 12:20	<i>Scientific Session 11: What have we got outside our box of drugs?</i> G. Doherty, Dublin, Ireland J. Panes, Barcelona, Spain
10:50 - 11:10	<i>68: The multi-refractory paediatric patients: Out of the box therapeutic treatments</i> D. Wilson, Edinburgh, United Kingdom
11:10 - 11:20	<i>69: OP38: Top-down infliximab superior to step-up in children with Moderate-to-Severe Crohn's Disease – A multicenter randomized controlled trial</i> M. Jongsma, Rotterdam, The Netherlands
11:20 - 11:40	<i>70: Drugs of the future: Update on developmental agents</i> W. Sandborn, La Jolla, United States
11:40 - 11:50	<i>71: OP39: Treatment of Ulcerative Colitis with AMT-101, a novel oral Interleukin-10 Immunomodulatory fusion biologic that traffics across intestinal epithelium</i> R. Msrny, San Francisco, United States
11:50 - 12:00	<i>72: OP40: A core transferable microbiota in responders to faecal microbiota transplant for Ulcerative Colitis shape mucosal T-Cell immunity</i> R. Longman, New York, United States
12:00 - 12:20	<i>73: Pathology guided surgery</i> P. Borralho Nunes, Lisbon, Portugal A. Spinelli, Rozzano, Italy
12:20 - 12:50	<i>Scientific Session 12: ECCO Lecture</i> S. Danese, Milan, Italy L. Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France J. van der Woude, Rotterdam, The Netherlands
12:20 - 12:50	<i>74: ECCO Lecture: How organoids model human disease</i> H. Clevers, Utrecht, The Netherlands
12:50 - 13:05	<i>75: Awards and Closing remarks</i> S. Danese, Milan, Italy J. van der Woude, Rotterdam, The Netherlands
13:05 - 13:15	<i>ECCO Film</i>

OP = Oral presentation – Best abstracts

Digital oral presentations (DOP)

Thursday, February 13, 2020

Lehar 1-3, Lehar 4, Strauss 1-2, Strauss 3, Stolz 1-2

17:30 - 18:30 Digital Oral Presentations Sessions 1-5

Digital Oral Presentation Session 1	<i>Diet & bugs: The Folie à deux of IBD</i> Room: Stolz 1-2 A. Levine, Holon, Israel E. Wine, Edmonton, Canada
Digital Oral Presentation Session 2	<i>Assesment of disease and therapy response</i> Room: Lehar 1-3 G. Doherty, Dublin, Ireland F. Magro Dias, Porto, Portugal
Digital Oral Presentation Session 3	<i>Improving care of IBD</i> Room: Lehar 4 G. Fiorino, Milan, Italy A. Hart, Harrow, United Kingdom
Digital Oral Presentation Session 4	<i>From the bench to the crystal ball: Predicting outcomes with novel markers</i> Room: Strauss 1-2 A. Armuzzi, Rome, Italy Y. Chowers, Haifa, Israel
Digital Oral Presentation Session 5	<i>Risks of disease, hazard of drugs</i> Room: Strauss 3 L. Beaugerie, Paris, France K. Katsanos, Ioannina, Greece

Friday, February 14, 2020

Lehar 1-3, Lehar 4, Strauss 1-2, Strauss 3, Stolz 1-2

17:25 - 18:25 Digital Oral Presentations Sessions 6-10

Digital Oral Presentation Session 6	<i>New insights into pathogenesis of IBD</i> Room: Stolz 1-2 L. Egan, Galway, Ireland C. Hedin, Stockholm, Sweden
Digital Oral Presentation Session 7	<i>Comparing outcomes of biologic treatments for IBD</i> Room: Lehar 1-3 M. Ferrante, Leuven, Belgium K. Gecse, Amsterdam, The Netherlands
Digital Oral Presentation Session 8	<i>Current and novel targets for IBD agents</i> Room: Lehar 4 J. Rivera-Nieves, San Diego, United States B. Siegmund, Berlin, Germany
Digital Oral Presentation Session 9	<i>Treatments for drug failing patients</i> Room: Strauss 1-2 S. Ben-Horin, Ramat Gan, Israel P. Lakatos, Budapest, Hungary; Montreal, Canada
Digital Oral Presentation Session 10	<i>Fighting the F's: Fat and fibrosis in IBD</i> Room: Strauss 3 F. Rieder, Cleveland, United States G. Rogler, Zurich, Switzerland

Hard copy poster presentations/ Poster exhibition

Opening Hours

<i>Industry and Poster exhibition</i>	
Wednesday, February 12, 2020	<i>Closed</i>
Thursday, February 13, 2020	10:30 - 18:00
Friday, February 14, 2020	08:00 - 18:00
Saturday, February 15, 2020	08:00 - 13:00

Guided poster session

The guided poster session is on **Friday, February 14, 2020** from **12:30 to 13:30** in the Exhibition Hall (Hall C).

In pairs, poster session chairs will guide groups through the poster exhibition and presenting authors will have the opportunity to share the major findings of their abstracts in 1-2 minutes. In that time, delegates will have the chance to engage with the abstract authors and directly ask any questions.

To join the guided poster session, please choose one of the poster groups listed on the next pages and find the respective poster chairs near the poster exhibition at 12:30 on Friday, February 14, 2020. All poster chairs carry an "ECCO Poster Chair" button and also hold a sign that states the poster group number as well as the scientific category.

Poster exhibition

In order to view the list with ECCO'20 abstracts presented as hard copy posters, please follow the links stated or scan the QR-codes in each category.

- (i) **Basic Science**
Poster P001-P114
ecco-ibd.eu/bs



- (ii) **Clinical: Diagnosis and Outcome**
Poster P115-P324
ecco-ibd.eu/cd



- (iii) **Clinical: Therapy and Observation**
Poster P325-P739
ecco-ibd.eu/ct



- (iv) **Epidemiology**
Poster P740-P819
ecco-ibd.eu/epi



- (v) **Genetics**
Poster P820-P830
ecco-ibd.eu/gen



- (vi) **Microbiology**
Poster P831-P853
ecco-ibd.eu/mb



- (vii) **Nurses abstracts**
Poster N01-N31
ecco-ibd.eu/np



Guided poster sessions are chaired by:

(i) Basic Science:

- Group 1** (starts at **P001**): R. Atreya, Erlangen, Germany
M. Scharl, Zurich, Switzerland
- Group 2** (starts at **P030**): P. Borralho Nunes, Lisbon, Portugal
G. Rogler, Zurich, Switzerland
- Group 3** (starts at **P059**): K. Gerasimidis, Glasgow, United Kingdom
M. Tripathi, Cambridge, United Kingdom
- Group 4** (starts at **P087**): T. Ahmad, Exeter, United Kingdom
C. Hedin, Stockholm, Sweden

(ii) Clinical: Diagnosis & Outcome:

- Group 5** (starts at **P115**): R. Feakins, London, United Kingdom
T. Raine, Cambridge, United Kingdom
- Group 6** (starts at **P145**): P. Eder, Poznan, Poland
TBC
- Group 7** (starts at **P175**): L. de Ridder, Rotterdam, The Netherlands
D. Wilson, Edinburgh, United Kingdom
- Group 8** (starts at **P205**): G. De Hertogh, Leuven, Belgium
J. van der Woude, Rotterdam, The Netherlands
- Group 9** (starts at **P235**): Y. Chowers, Haifa, Israel
I. da Luz Rosa, Lisbon, Portugal
- Group 10** (starts at **P265**): P. Ellul, Msida, Malta
N. Yassin, Birmingham, United Kingdom
- Group 11** (starts at **P295**): G. Mantzaris, Athens, Greece
F. Rosini, London, United Kingdom

(iii) Clinical: Therapy and Observation:

- Group 12** (starts at **P325**): M. Adamina, Winterthur, Switzerland
N. Arebi, Harrow, United Kingdom
- Group 13** (starts at **P355**): D. Bettenworth, Münster, Germany
L. Egan, Galway, Ireland
- Group 14** (starts at **P385**): G. Cullen, Dublin, Ireland
G. Doherty, Dublin, Ireland
- Group 15** (starts at **P415**): K. Gecse, Amsterdam, The Netherlands
J. Gisbert, Madrid, Spain
- Group 16** (starts at **P445**): J. Halfvarson, Örebro, Sweden
P. Irving, London, United Kingdom
- Group 17** (starts at **P475**): A. Hart, Harrow, United Kingdom
P. Juillerat, Bern, Switzerland
- Group 18** (starts at **P505**): W. Bemelman, Amsterdam, The Netherlands
K. Katsanos, Ioannina, Greece
- Group 19** (starts at **P535**): P. Kienle, Mannheim, Germany
P. Kotze, Curitiba, Brazil

- Group 20** (starts at **P565**): I. Lyutakov, Sofia, Bulgaria
J. Warusavitarne, Harrow, United Kingdom
- Group 21** (starts at **P595**): E. Langholz, Herlev, Denmark
N. Noor, Cambridge, United Kingdom
- Group 22** (starts at **P625**): N. Ding, Fitzroy, Australia
J. Torres, Loures, Portugal
- Group 23** (starts at **P653**): S. Restellini, Geneva, Switzerland
S. Zeissig, Dresden, Germany
- Group 24** (starts at **P682**): P. Michetti, Lausanne, Switzerland
P. Myrelid, Linköping, Sweden
- Group 25** (starts at **P711**): J. Conde Aranda, Zurich, Switzerland
F. Rieder, Cleveland, United States

(iv) Epidemiology:

- Group 26** (starts at **P740**): L. Beaugerie, Paris, France
J. Kirchgesner, Paris, France
- Group 27** (starts at **P767**): P. Lakatos, Budapest, Hungary;
Montreal Canada
M. Pierik, Maastricht, The Netherlands
- Group 28** (starts at **P794**): D. Turner, Jerusalem, Israel
H. Yanai, Tel Aviv, Israel

(v) Genetics:

- Group 29** (starts at **P820**): M. Parkes, Cambridge, United Kingdom
M. Svrcek, Paris, France

(vi) Microbiology:

- Group 30** (starts at **P831**): J. Van Limbergen, Amsterdam,
The Netherlands
E. Wine, Edmonton, Canada

Educational programme

ECCO aims to promote education and improve the quality of care for IBD patients throughout Europe. Thus, ECCO offers the following educational activities prior to as well as during the 15th Congress of ECCO in Vienna.

2nd ECCO-ESGAR Basic Imaging Workshop – Group A



Date: Wednesday, February 12, 2020
Time: 07:30-18:00
Organisation: EduCom in collaboration with ESGAR
Target audience: Physicians, Radiologists, Surgeons, Paediatricians
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: 7 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, February 12, 2020
Lehar 4, Ground Level, Reed Messe Wien – Group A
(as of January 15, 2020)

07:30 - 07:45	1A: Welcome & Introduction, Pre-course voting J. Lindsay London United Kingdom M. Iacucci, Birmingham, United Kingdom
07:45 - 09:20	Session 1: Endoscopy – Advanced endoscopic assessment of inflammation and mucosal healing R. Kiesslich, Wiesbaden, Germany
07:45 - 08:05	2A: Is Endoscopy getting closer to histology in assessment of inflammation and mucosal healing M. Iacucci, Birmingham, United Kingdom
08:05 - 08:25	3A: Interactive video cases: How to score endoscopy in IBD and what to look for F. Furfaro, Milan, Italy
08:25 - 08:45	4A: Video capsule endoscopy or enteroscopy to assess small bowel Crohn's Disease: Which comes first? R. Sidhu, Sheffield, United Kingdom
08:45 - 09:20	5A: Interactive video cases: What I am seeing in the small bowel U. Kopylov, Tel Aviv, Israel P. Ellul, Msida, Malta
09:20 - 09:45	Coffee break

09:45 - 10:30	<i>Session 2: Endoscopy – New future at the horizon to characterise and treat colonic dysplasia: Does optical diagnosis really help?</i> B. Shen, Cleveland, USA
09:45 - 10:10	<i>6A: Advanced dysplasia characterisation and therapeutic management: How deep can I go to resect?</i> R. Kiesslich, Wiesbaden, Germany
10:10 - 10:30	<i>7A: Interactive video cases in dysplasia: What to look for and how to do it?</i> M. Iacucci, Birmingham, United Kingdom R. Kiesslich, Wiesbaden, Germany
10:30 - 11:30	<i>Session 3: Endoscopy – Therapeutic interventions in IBD: Can it spare surgical resections?</i> P. Ellul, Msida, Malta
10:30 - 10:50	<i>8A: Therapeutic colonoscopic interventions in strictures, fistulae and pouches – can it replace surgery in selected patients? Interactive discussion</i> B. Shen, Cleveland, United States
10:50 - 11:30	<i>9A: Interactive video cases: Can I also do it?</i> P. Kotze, Curitiba, Brazil B. Shen, Cleveland, United States
11:30 - 12:00	<i>10A: Closing remarks and post course voting</i> M. Iacucci, Birmingham, United Kingdom
12:00 - 13:30	Lunch break

Lehar 3, Ground Level, Reed Messe Wien – Group A (as of January 15, 2020)

13:30 - 13:40	<i>11A: Welcome & Introduction</i> P. Paolantonio, Rome, Italy C. Maaser, Lüneburg, Germany
13:40 - 14:10	<i>Ultrasound and MRI – Introductory lectures</i>
13:40 - 13:55	<i>12A: Entero-MRI – what to look for</i> M. Amitai, Tel Aviv, Israel
13:55 - 14:10	<i>13A: Intestinal ultrasound – what to look for</i> G. Maconi, Milan, Italy

14:10 - 15:40	Ultrasound and MRI – Hands-on bowel ultrasonography and interactive discussion on Ultrasound MRI workstations – Part 1
14:10 - 15:40	Management of suspected IBD W. Tillinger, Vienna, Austria M. Amitai, Tel Aviv, Israel Assessment of Crohn's Disease activity K. Novak, Calgary, Canada P. Paolantonio, Rome, Italy Intestinal complications of Crohn's Disease R. Wilkens, Copenhagen, Denmark A. Gupta, London, United Kingdom Post-operative recurrence of Crohn's Disease G. Rogler, Zurich, Switzerland C. Bonifacio, Rozzano, Italy Perianal Crohn's Disease C. Maaser, Lüneburg, Germany A. Ba-Ssalamah, Vienna, Austria Ulcerative Colitis J. Buchkremer, Berlin, Germany A. Radmard, Tehran, Iran
15:40 - 16:10	Ultrasound and MRI – lectures Part 2
15:40 - 16:10	14A: When IUS, when MRI in daily IBD practice? F. Maccioni, Rome, Italy K. Novak, Calgary, Canada
16:10 - 17:40	Ultrasound and MRI – Hands-on bowel ultrasonography and interactive discussion on Ultrasound MRI workstations – Part 2
16:10 - 17:40	Management of suspected IBD W. Tillinger, Vienna, Austria M. Amitai, Tel Aviv, Israel Assessment of Crohn's Disease activity K. Novak, Calgary, Canada P. Paolantonio, Rome, Italy Intestinal complications of Crohn's Disease R. Wilkens, Copenhagen, Denmark A. Gupta, London, United Kingdom Post-operative recurrence of Crohn's Disease G. Rogler, Zurich, Switzerland C. Bonifacio, Rozzano, Italy Perianal Crohn's Disease C. Maaser, Lüneburg, Germany A. Ba-Ssalamah, Vienna, Austria Ulcerative Colitis J. Buchkremer, Berlin, Germany A. Radmard, Tehran, Iran
17:40 - 18:00	15A: Post-course voting and farewell P. Paolantonio, Rome, Italy C. Maaser, Lüneburg, Germany

2nd ECCO-ESGAR Basic Imaging Workshop – Group B



Date: Wednesday, February 12, 2020
Time: 07:30-18:00
Organisation: EduCom in collaboration with ESGAR
Target audience: Physicians, Radiologists, Surgeons, Paediatricians
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: 7 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, February 12, 2020

*Lehar 3, Ground Level, Reed Messe Wien – Group B
(as of January 15, 2020)*

07:30 - 07:40	1B: Welcome & Introduction P. Paolantonio, Rome, Italy C. Maaser, Lüneburg, Germany
07:40 - 08:10	Ultrasound and MRI – Introductory lectures
07:40 - 07:55	2B: Entero-MRI – what to look for M. Amitai, Tel Aviv, Israel
07:55 - 08:10	3B: Intestinal ultrasound – what to look for G. Maconi, Milan, Italy
08:10 - 09:40	Ultrasound and MRI – Hands-on bowel ultrasonography and interactive discussion on Ultrasound MRI workstations – Part 1
08:10 - 09:40	Management of suspected IBD T. Kucharzik, Lüneburg, Germany J. Rimola, Barcelona, Spain Assessment of Crohn's Disease activity K. Novak, Calgary, Canada P. Paolantonio, Rome, Italy Intestinal complications of Crohn's Disease R. Wilkens, Copenhagen, Denmark A. Gupta, London, United Kingdom Post-operative recurrence of Crohn's Disease J. Buchkremer, Berlin, Germany C. Bonifacio, Rozzano, Italy Perianal Crohn's Disease G. Maconi, Milan, Italy F. Maccioni, Rome, Italy Ulcerative Colitis K. Gecse, Amsterdam, The Netherlands A. Radmard, Tehran, Iran
09:40 - 10:10	Ultrasound and MRI – lectures Part 2
09:40 - 10:10	4B: When IUS, when MRI in daily IBD practice? F. Maccioni, Rome, Italy K. Novak, Calgary, Canada

10:10 - 11:40	<i>Ultrasound and MRI – Hands-on bowel ultrasonography and interactive discussion on Ultrasound MRI workstations – Part 2</i>
10:10 - 11:40	<i>Management of suspected IBD</i> T. Kucharzik, Lüneburg, Germany J. Rimola, Barcelona, Spain <i>Assessment of Crohn's Disease activity</i> K. Novak, Calgary, Canada P. Paolantonio, Rome, Italy <i>Intestinal complications of Crohn's Disease</i> R. Wilkens, Copenhagen, Denmark A. Gupta, London, United Kingdom <i>Post-operative recurrence of Crohn's Disease</i> J. Buchkremer, Berlin, Germany C. Bonifacio, Rozzano, Italy <i>Perianal Crohn's Disease</i> G. Maconi, Milan, Italy F. Maccioni, Rome, Italy <i>Ulcerative Colitis</i> K. Gecse, Amsterdam, The Netherlands A. Radmard, Tehran, Iran
11:40 - 12:00	<i>5B: Post-course voting and farewell</i> P. Paolantonio, Rome, Italy C. Maaser, Lüneburg, Germany
12:00 - 13:30	<i>Lunch break</i>
<i>Lehar 4, Ground Level, Reed Messe Wien – Group B (as of January 15, 2020)</i>	
13:30 - 13:45	<i>6B: Welcome & Introduction, Pre-course voting</i> P. Juillerat, Bern, Switzerland M. Iacucci, Birmingham, United Kingdom
13:45 - 15:20	<i>Session 1: Endoscopy – Advanced endoscopic assessment of inflammation and mucosal healing</i> R. Kiesslich, Wiesbaden, Germany
13:45 - 14:05	<i>7B: Is Endoscopy getting closer to histology in assessment of inflammation and mucosal healing</i> M. Iacucci, Birmingham, United Kingdom
14:05 - 14:25	<i>8B: Interactive video cases: How to score endoscopy in IBD and what to look for</i> F. Furfarò, Milan, Italy
14:25 - 14:45	<i>9B: Video capsule endoscopy or enteroscopy to assess small bowel Crohn's Disease: Which comes first?</i> R. Sidhu, Sheffield, United Kingdom
14:45 - 15:20	<i>10B: Interactive video cases: What I am seeing in the small bowel</i> R. Sidhu, Sheffield, United Kingdom U. Kopylov, Tel Aviv, Israel
15:20 - 15:45	<i>Coffee break</i>

15:45 - 16:30	<i>Session 2: Endoscopy – New future at the horizon to characterise and treat colonic dysplasia: Does optical diagnosis really help?</i> B. Shen, Cleveland, USA
15:45 - 16:10	<i>11B: Advanced dysplasia characterisation and therapeutic management: How deep can I go to resect?</i> R. Kiesslich, Wiesbaden, Germany
16:10 - 16:30	<i>12B: Interactive video cases in dysplasia: What to look for and how to do it?</i> M. Iacucci, Birmingham, United Kingdom R. Kiesslich, Wiesbaden, Germany
16:30 - 17:30	<i>Session 3: Endoscopy – Therapeutic interventions in IBD: Can it spare surgical resections?</i> P. Ellul, Msida, Malta
16:30 - 16:50	<i>13B: Therapeutic colonoscopic interventions in strictures, fistulae and pouches – Can it replace surgery in selected patients? Interactive discussion</i> B. Shen, Cleveland, United States
16:50 - 17:30	<i>14B: Interactive video cases: Can I also do it?</i> P. Kotze, Curitiba, Brazil B. Shen, Cleveland, United States
17:30 - 18:00	<i>15B: Closing remarks and post course voting</i> M. Iacucci, Birmingham, United Kingdom

18th IBD Intensive Advanced Course

Date:	Wednesday-Thursday, February 12-13, 2020
Time:	Wednesday, February 12: 08:00-17:00 Thursday, February 13: 07:30-12:00
Organisation:	EduCom
Target audience:	Junior gastroenterologists
Registration:	ECCO Membership 2020 required. No onsite registration.
CME accreditation:	10 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, February 12, 2020

*Strauss 3, Ground Level, Reed Messe Wien
(as of January 15, 2020)*

08:00 - 08:15	Arrival & download of ECCO IBD App
08:15 - 08:30	1: Welcome & Introduction from the course director S. Danese, Milan, Italy J. Lindsay, London, United Kingdom P. Juillerat, Bern, Switzerland
08:30 - 10:30	Session 1: Introduction and case-based management on conventional IBD Therapies Lead discussant: J. Lindsay, London, United Kingdom
08:30 - 09:00	2: IBD: Epidemiology, immunopathogenesis, and their relevance to therapeutics I. Dotan, Petah Tikva, Israel
09:00 - 09:20	3: 5-ASA compounds H. Yanai, Petah Tikva, Israel
09:20 - 09:40	4: Thiopurines P. Irving, London, United Kingdom
09:40 - 10:00	5: Methotrexate P. Juillerat, Bern, Switzerland
10:00 - 10:20	6: Steroids K. Katsanos, Ioannina, Greece
10:20 - 10:30	Discussion
10:30 - 10:50	Coffee break
10:50 - 12:30	Session 2: Case-based management of conventional IBD Therapies Lead discussant: A. Dignass, Frankfurt, Germany
10:50 - 11:10	7: Anti-TNF agents P. Michetti, Lausanne, Switzerland
11:10 - 11:30	8: Anti-integrins J. Lindsay, London, United Kingdom
11:30 - 11:50	9: Ustekinumab S. Vermeire, Leuven, Belgium

11:50 - 12:10	10: Tofacitinib F. Rieder, Cleveland, United States
12:10 - 12:30	11: Small molecules and biologics in the pipeline L. Peyrin-Biroulet, Vandoeuvre-les-Nancy, France
12:30 - 14:00	Lunch break
14:00 - 15:30	Session 3: Round tables – 7 Themes / clinical cases discussion – Part 1
14:00 - 15:30	12a: Pregnancy J. van der Woude, Rotterdam, The Netherlands I. Dotan, Petah Tikva, Israel 12b: Extraintestinal manifestations K. Katsanos, Ioannina, Greece P. Lakatos, Budapest, Hungary; Montreal, Canada 12c: When and how to stop biologics? A. Dignass, Frankfurt, Germany G. Mantzaris, Athens, Greece 12d: Complications associated with anti-TNF therapy S. Ben-Horin, Ramat Gan, Israel Y. Chowers, Haifa, Israel 12e: Therapeutic Drug Monitoring P. Juillerat, Bern, Switzerland F. Baert, Roeselare, Belgium 12f: Exit strategy M. Ferrante, Leuven, Belgium J. Torres, Loures, Portugal 12g: Endoscopy in IBD P. Michetti, Lausanne, Switzerland H. Yanai, Petah Tikva, Israel
15:30 - 15:50	Coffee break
15:50 - 17:00	Session 3: Round tables – 7 Themes / clinical cases discussion – Part 2
15:50 - 17:00	12a: Pregnancy J. van der Woude, Rotterdam, The Netherlands I. Dotan, Petah Tikva, Israel 12b: Extraintestinal manifestations K. Katsanos, Ioannina, Greece P. Lakatos, Budapest, Hungary; Montreal, Canada 12c: When and how to stop biologics? A. Dignass, Frankfurt, Germany G. Mantzaris, Athens, Greece 12d: Complications associated with anti-TNF therapy S. Ben-Horin, Ramat Gan, Israel Y. Chowers, Haifa, Israel 12e: Therapeutic Drug Monitoring P. Juillerat, Bern, Switzerland F. Baert, Roeselare, Belgium 12f: Exit strategy M. Ferrante, Leuven, Belgium J. Torres, Loures, Portugal 12g: Therapeutic Endoscopy in IBD P. Michetti, Lausanne, Switzerland H. Yanai, Petah Tikva, Israel



European
Crohn's and Colitis
Organisation

UR-CARE



United
Assess



Registries for Clinical
Assessment and **RE**search

The IBD Database for your patient records and your research studies

What to expect:

- Comprehensive registry capturing demographics, environmental factors, clinical characteristics, examinations and therapeutic interventions in IBD
- Retro- & prospective data collection and evaluation
- Autonomous data management offered to study groups
- Precise data ownership rules

Scan and visit

www.ecco-ibd.eu/ur-care



Thursday, February 12, 2020

Strauss 3, Ground Level, Reed Messe Wien

(as of January 15, 2020)

Session 4: Interactive case discussions	
07:30 - 09:30	Lead discussants: P. Juillerat, Bern, Switzerland A. López-Sanromán, Madrid, Spain
07:30 - 08:00	13: Investigation and management of early Mild/Moderate Crohn's Disease Case presentation: T. Raine, Cambridge, United Kingdom Discussion: L. Egan, Galway, Ireland
08:00 - 08:05	Discussion
08:05 - 08:40	14: Management of perianal CD A. López-Sanromán, Madrid, Spain P. Kotze, Curitiba, Brazil
08:40 - 08:45	Discussion
08:45 - 09:30	15: Optimal management of patient with Severe Crohn's Disease treated with anti-TNF agents Case presentation: D. Bettenworth, Münster, Germany Discussion: P. Juillerat, Bern, Switzerland P. Kotze, Curitiba, Brazil
09:30 - 09:45 Coffee break	
Session 5: Special case scenarios	
09:45 - 11:45	Lead discussant: G. Mantzaris, Athens, Greece
09:45 - 10:15	16: Management of refractory pouchitis I. Dotan, Petah Tikva, Israel
10:15 - 10:45	17: Management of Acute Severe Ulcerative Colitis D. Laharie, Pessac, France
10:45 - 11:15	18: Pre- and postoperative management of Crohn's Disease G. Doherty, Dublin, Ireland
11:15 - 11:45	Discussion
11:45 - 12:00	19: Feedback & Closing remarks P. Juillerat, Bern, Switzerland



European
Crohn's and Colitis
Organisation

ECCO'20 Webcasts



Missed an excellent presentation at the Congress?

- Watch video recordings of ECCO'20 and past Congresses on the e-CCO Learning Platform
- Accessible for all ECCO Members
- Scientific programme webcasts
- New: Digital oral presentation webcasts
- Educational programme webcasts:
 - 2nd ECCO-ESGAR Basic Imaging Workshop
 - 5th H-ECCO IBD Masterclass
 - 8th SciCom Workshop
 - 11th N-ECCO School

Scan and visit

www.e-learning.ecco-ibd.eu



11th N-ECCO School

Date: Wednesday, February 12, 2020
Time: 08:30-16:45
Organisation: N-ECCO
Target audience: IBD Nurses, Dietitians
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: N/A

Wednesday, February 12, 2020

Schubert 1-3, Level 1, Reed Messe Wien (as of Jan. 15, 2020)

08:30 - 08:45	1: Welcome & Introduction M. Ganon, Jerusalem, Israel
08:45 - 12:15	Session 1: Diagnosis and assessment M. Ganon, Jerusalem, Israel M. Campmans-Kuijpers, Groningen, The Netherlands
08:45 - 09:30	2: Diagnosis, anatomy and physiology in IBD M. Ferrante, Leuven, Belgium
09:30 - 10:00	3: Psychosocial implications of living with IBD W. Czubor-Dochan, London, United Kingdom
10:00 - 10:30	4: Nutritional assessment in IBD L. Godny, Petah Tikva, Israel
10:30 - 10:45	Coffee break
10:45 - 11:15	5: Surgery in IBD M. Adamina, Winterthur, Switzerland
11:15 - 11:45	6: Medical treatment D. Bettenworth, Münster, Germany
11:45 - 12:15	7: Adherence S. Jäghult, Stockholm, Sweden
12:15 - 13:45	Lunch break
12:30 - 13:30	N-ECCO School Lunch Satellite Symposium
13:45 - 15:15	Session 2: Case studies – Disease management P. Hartmann, Minden, Germany A. Ibarra, London, United Kingdom
13:45 - 14:30	8: UC Management M. Samaan, London, United Kingdom
14:30 - 15:15	9: CD Management M. Pierik, Maastricht, The Netherlands
15:15 - 15:30	Coffee break
15:30 - 16:30	Session 3: Multidisciplinary management in IBD P. Hartmann, Minden, Germany E. Wine, Edmonton, Canada
15:30 - 16:00	10: Nutritional management in IBD C. Wall, Christchurch, New Zealand
16:00 - 16:30	11: Nursing roles in IBD management A. Ibarra, London, United Kingdom
16:30 - 16:45	12: Closing remarks M. Ganon, Jerusalem, Israel

5th Basic ECCO: EduCational COurse for Industry

Date: Wednesday, February 12, 2020
Time: 10:00-17:00
Organisation: ClinCom
Target audience: Corporate Members & Non-Corporate Members
Registration: ECCO Membership 2020 NOT required. No onsite registration.
CME accreditation: N/A

Wednesday, February 12, 2020

*Stolz 1-2, Ground Level, Reed Messe Wien
(as of January 15, 2020)*

10:00 - 10:05	1: Welcome L. Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France
10:05 - 12:00	Session 1: Natural history and overall management L. Beaugerie, Paris, France
10:05 - 10:25	2: What is IBD? Patient and physician perspective W. Reinisch, Vienna, Austria E. Groß, Graz, Austria
10:25 - 10:40	3: What causes IBD? T. Raine, Cambridge, United Kingdom
10:40 - 10:55	4: Diagnosis and assessing disease activity P. Bossuyt, Bonheiden, Belgium
10:55 - 11:10	5: Extraintestinal manifestations G. Rogler, Zurich, Switzerland
11:10 - 11:25	6: Risk factors for complicated outcome S. Sebastian, Hull, United Kingdom
11:25 - 11:35	Question time
11:35 - 12:00	7: Role of multidisciplinary teams in IBD C. Buskens, Amsterdam, The Netherlands P. Irving, London, United Kingdom A. Fraser, Bristol, United Kingdom
12:00 - 13:00	Lunch break

13:00 - 14:40	Session 2: IBD Therapy P. Bossuyt, Bonheiden, Belgium
13:00 - 13:15	8: What is the role of 5-ASA and steroids? U. Kopylov, Tel Aviv, Israel
13:15 - 13:30	9: What is the role of immunomodulators? J. Gisbert, Madrid, Spain
13:30 - 13:45	10: What about biological therapy? T. Ahmad, Exeter, United Kingdom
13:45 - 14:00	11: Small molecules and future treatment options G. D'Haens, Amsterdam, The Netherlands
14:00 - 14:15	12: How to choose between treatment modalities? Treatment target and individualised treatment options S. Vermeire, Leuven, Belgium
14:15 - 14:30	13: How to maximise safety? Cancer surveillance L. Beaugerie, Paris, France
14:30 - 14:40	Question time
14:40 - 15:00	Coffee break
15:00 - 16:15	Session 3: Medical – surgical interface S. Sebastian, Hull, United Kingdom
15:00 - 15:20	14: Perianal Crohn's Disease W. Bemelman, Amsterdam, The Netherlands K. Gecse, Amsterdam, The Netherlands
15:20 - 15:40	15: Surgery and postoperative follow-up for luminal Crohn's Disease A. Spinelli, Milan, Italy G. Fiorino, Milan, Italy
15:40 - 16:00	16: Surgery and pouch complications in Ulcerative Colitis A. Hart, Harrow, United Kingdom J. Warusavitarne, Harrow, United Kingdom
16:00 - 16:15	Question time
16:15 - 17:00	Session 4: Future perspectives K. Gecse, Amsterdam, The Netherlands
16:15 - 16:35	17: The IBD quiz for industry K. Gecse, Amsterdam, The Netherlands
16:35 - 16:55	18: Where is the unmet need for patients with IBD? J. Panes, Barcelona, Spain
16:55 - 17:00	19: Closing remarks K. Gecse, Amsterdam, The Netherlands

6th Y-ECCO Basic Science Workshop

Date:	Wednesday, February 12, 2020
Time:	12:30-16:30
Organisation:	Y-ECCO
Target audience:	Basic scientists, Physicians, Paediatricians, Surgeons, IBD Nurses
Registration:	ECCO Membership 2020 required. No onsite registration.
CME accreditation:	3 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, February 12, 2020

Schubert 4-5, Level 1, Reed Messe Wien
(as of January 15, 2020)

12:30 - 12:35	1: Introduction C. Hedin, Stockholm, Sweden
12:35 - 13:50	Session 1: Inflammation at the interface D. Bettenworth, Münster, Germany H. Clevers, Utrecht, The Netherlands
12:35 - 13:05	2: Gut Organoids: Patients' avatars in the lab H. Clevers, Utrecht, The Netherlands
13:05 - 13:20	3: Abstract presentation: Cytokine responsive transcriptional networks in Inflammatory Bowel Disease A. Treveil, Norwich, United Kingdom
13:20 - 13:35	4: Abstract presentation: Multi-'omics profiling in patients with quiescent Inflammatory Bowel Disease identifies biomarkers predicting relapse N. Borren, Amsterdam, The Netherlands
13:35 - 13:50	5: Abstract presentation: Integrated network analysis using patient-specific single nucleotide polymorphism profiles uncovers new pathways involved in Ulcerative Colitis pathogenesis D. Modos, Cambridge, United Kingdom
13:50 - 14:15	Meet the speakers break

14:15 - 15:30	Session 2: Basic science from bench to bedside C. Hedin, Stockholm, Sweden C. Buskens, Amsterdam, The Netherlands
14:15 - 14:45	6: Translational Basic Science Research C. Buskens, Amsterdam, The Netherlands
14:45 - 15:00	7: Abstract presentation: Macrophages in Crohn's Disease mesentery are predominantly inflammatory and produce calprotectin M. Becker, Amsterdam, The Netherlands
15:00 - 15:15	8: Abstract presentation: The molecular landscape of perianal fistula in Crohn's Disease: Opportunities for new therapeutic approaches B. Verstockt, Leuven, Belgium
15:15 - 15:30	9: Abstract presentation: Combination of vedolizumab with tacrolimus is more efficient in reducing intestinal inflammation than vedolizumab alone in the DSS-induced acute colitis mouse model R. Manzini, Zurich, Switzerland
15:30 - 16:15	Session 3: Basic Science Research Fellowships M. Samaan, London, United Kingdom G. Pellino, Aversa, Italy
15:30 - 15:45	10: The role of Nlrp9b, a novel NLR member in regulating experimental colitis D. Zheng, Guangzhou, China
15:45 - 16:00	11: PTPN2 and TiO2 in the pathogenesis of Inflammatory Bowel Disease J. Conde Aranda, Zurich, Switzerland
16:00 - 16:15	12: The role of fibroblasts in the pathogenesis of Crohn's Disease-associated fistulas and in mesenchymal stem cell therapy R. Bruckner, Leiden, The Netherlands
16:15 - 16:30	13: Closing remarks and Y-ECCO best abstract awards D. Bettenworth, Münster, Germany

5th EpiCom Workshop

Date: Wednesday, February 12, 2020
Time: 13:30-17:00
Organisation: EpiCom
Target audience: Physicians, Surgeons, Paediatricians, IBD Nurses
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: 3 CME Credits; prerequisite: completion of the online evaluation form.

Wednesday, February 12, 2020

*Lehar 2, Ground Level, Reed Messe Wien
 (as of January 15, 2020)*

13:30 - 13:40	1: Welcome & Introduction M. Pierik, Maastricht, The Netherlands
13:40 - 15:30	Session 1: The value of patient reported outcomes measures in 2020 and beyond V. Pittet, Lausanne, Switzerland J. Kirchgesner, Paris, France
13:40 - 14:00	2: Definition, reliability and validity of PROs for clinical epidemiology B. Alizadeh, Groningen, The Netherlands
14:00 - 14:20	3: Using patient reported outcomes to improve Health Care Quality K. Gibson, Ayr, United Kingdom
14:20 - 14:50	4: Outcomes meaningful to patients in IBD drug development J. Colombel, New York, United States
14:50 - 15:00	5: Value of PROs: Perspective of EpiCom workshop participants N. Arebi, Harrow, United Kingdom
15:00 - 15:30	6: Interactive session: Implementation of PROs – Part I
15:30 - 15:50	Coffee break
15:50 - 16:50	Session 2: Implementation of PRO in daily practice and research V. Pittet, Lausanne, Switzerland J. Kirchgesner, Paris, France
15:50 - 16:20	7: Interactive session: Implementation of PROs – Part II
16:20 - 16:50	8: The PROMise of remote monitoring tools in IBD daily care P. Munkholm, Frederikssund, Denmark M. Pierik, Maastricht, The Netherlands
16:50 - 17:00	9: Take home message & Farewell N. Arebi, Harrow, United Kingdom

6th N-ECCO Research Forum

Date: Wednesday, February 12, 2020
Time: 14:00-18:00
Organisation: N-ECCO
Target audience: IBD Nurses and Allied health professionals
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: N/A

Wednesday, February 12, 2020

*Strauss 1-2, Ground Level, Reed Messe Wien
 (as of January 15, 2020)*

14:00 - 14:10	1: Welcome & Introduction Present new awardees for 2020 W. Czuber-Dochan, London, United Kingdom
14:10 - 15:10	Session 1: Presentation by the previous N-ECCO Research Grant winners W. Czuber-Dochan, London, United Kingdom S. Jäghult, Stockholm, Sweden
14:10 - 14:30	2: Research Award Outcomes 2018 M. de Jong-van der Zee, Amsterdam, The Netherlands
14:30 - 14:50	3: Research Award Outcomes 2019 D. Farrell, Cork, Ireland
14:50 - 15:10	4: Research Award Outcomes 2020 S. Fourie, Oxford, United Kingdom K. Pihl Lesnovska, Linköping, Sweden
15:10 - 16:00	Session 2: The research journey W. Czuber-Dochan, London, United Kingdom S. Jäghult, Stockholm, Sweden
15:10 - 15:25	5: The journey of a novel researcher K. Greveson, London, United Kingdom
15:25 - 15:40	6: Developing research questions W. Czuber-Dochan, London, United Kingdom
15:40 - 16:00	7: 'Best' Methodologies for your project D. Farrell, Cork, Ireland S. Jäghult, Stockholm, Sweden
16:00 - 16:30	Coffee break
16:30 - 17:50	Session 3: Research projects planning W. Czuber-Dochan, London, United Kingdom S. Jäghult, Stockholm, Sweden
16:30 - 17:30	8: Workshops M. de Jong-van der Zee, Amsterdam, The Netherlands D. Farrell, Cork, Ireland S. Jäghult, Stockholm, Sweden W. Czuber-Dochan, London, United Kingdom
17:30 - 17:50	9: Short presentation of status from the workshops
17:50 - 18:00	10: Closing remarks W. Czuber-Dochan, London, United Kingdom

14th N-ECCO Network Meeting

Date: Thursday, February 13, 2020
Time: 09:00-17:00
Organisation: N-ECCO
Target audience: IBD Nurses - advanced level
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: N/A

Thursday, February 13, 2020

*Strauss 1-2, Ground Level, Reed Messe Wien
 (as of January 15, 2020)*

08:00 - 08:45	N-ECCO Network Meeting Breakfast Satellite Symposium
09:00 - 09:15	1: Welcome & Introduction S. Jäghult, Stockholm, Sweden
09:15 - 10:30	Session 1: Educational programme ECCO IBD Nurse Education Programme W. Czuber-Dochan, London, United Kingdom P. Hartmann, Minden, Germany
09:15 - 10:00	2: Developing a European IBD Nurse Education Programme P. Bager, Aarhus, Denmark K. Kemp, Manchester, United Kingdom
10:00 - 10:30	3: Country perspective and benefits S. Radice, Milan, Italy G. Fiorino, Milan, Italy
10:30 - 11:00	Coffee break
11:00 - 12:30	Session 2: Improving clinical practice through high quality evidence M. Ganon, Jerusalem, Israel R. Lindenthaler, Schwarzach, Austria
11:00 - 11:45	4: The nursing perspective of Quality Standards of Care S. Jäghult, Stockholm, Sweden
11:45 - 12:00	5: N01: Factors related to self-medication with corticosteroids, aminosalicylates or analgesics and reasons given by patients with Ulcerative Colitis from Spain M. Cañas, Madrid, Spain
12:00 - 12:15	6: N02: The IBD-BOOST programme: Developing a digital self-management intervention for symptoms of fatigue, pain and urgency in Inflammatory Bowel Disease L. Sweeney, London, United Kingdom
12:15 - 12:30	7: N03: Disease burden of patients with Inflammatory Bowel Disease from the viewpoint of QOL and depression M. Takahashi, Tokyo, Japan

12:30 - 14:00	Lunch break
12:45 - 13:45	N-ECCO Network Meeting Lunch Satellite Symposium
14:00 - 14:45	Session 3: Multi-symptoms management in IBD W. Czuber-Dochan, London, United Kingdom A. Ibarra, London, United Kingdom
14:00 - 14:20	8: Methods of fatigue pain and incontinence management C. Norton, Buckinghamshire, United Kingdom
14:20 - 14:45	9: New treatments: Immunology explained A. Dignass, Frankfurt, Germany
14:45 - 15:15	Coffee break
15:15 - 16:30	Session 4: New developments in IBD S. Jäghult, Stockholm, Sweden T. Kasa, Vienna, Austria
15:15 - 15:45	10: MDT (multidiscipline) approach to managing the complex IBD Patient R. Panaccione, Calgary, Canada
15:45 - 16:30	11: Q&A Session D. O'Hanlon, London, United Kingdom A. Duff, London, United Kingdom P. Bager, Aarhus, Denmark W. Czuber-Dochan, London, United Kingdom R. Panaccione, Calgary, Canada
16:30 - 17:00	12: Closing remarks, N-ECCO in 2021 and beyond S. Jäghult, Stockholm, Sweden

9th S-ECCO IBD Masterclass in collaboration with ESCP

Date:	Thursday, February 13, 2020
Time:	07:30-17:00
Organisation:	S-ECCO in collaboration with ESCP
Target audience:	Surgeons, Physicians, IBD Nurses
Registration:	ECCO Membership 2020 required. No onsite registration.
CME accreditation:	6 CME Credits; prerequisite: completion of the online evaluation form.



Thursday, February 13, 2020

*Stolz 1-2, Ground Level, Reed Messe Wien
(as of January 15, 2020)*

07:30 - 07:40	1: Welcome Y. Panis, Clichy, France
07:40 - 09:30	Session 1: Hot debates in IBD surgery: We want a better pouch! M. Adamina, Winterthur, Switzerland Y. Panis, Clichy, France
07:40 - 08:25	Debate 1: What happens postoperatively?
07:40 - 07:55	2: Could prehabilitation improve the results? S. Vermeire, Leuven, Belgium
07:55 - 08:10	3: Pelvic early postoperative sepsis A. D'Hoore, Leuven, Belgium
08:10 - 08:25	Discussion
08:25 - 09:10	Debate 2: No early leak but function is bad!
08:25 - 08:40	4: Early pouch dysfunction W. Bemelman, Amsterdam, The Netherlands
08:40 - 08:55	5: Late problems H. Tulchinsky, Tel Aviv, Israel
08:55 - 09:10	Discussion
09:10 - 09:30	6: Misperception of IBD surgery A. Spinelli, Milan, Italy
09:30 - 10:00	Coffee break

10:00 - 11:30	Session 2: The scientific IBD surgeon: Trial updates and free papers H. Tulchinsky, Tel Aviv, Israel L. Peyrin-Biroulet, Vandœuvre-lès-Nancy, France
10:00 - 10:30	Trial updates
10:00 - 10:10	7: Mesh repair for ventral hernia in Crohn's Disease patients: A GETAID surgery case-matched multicentric study L. Beyer-Berjot, Marseille, France
10:10 - 10:20	8: Dysplasia and cancer in Ulcerative Colitis (A UR-CARE project) C. Buskens, Amsterdam, The Netherlands
10:20 - 10:30	9: I-CARE study L. Beaugerie, Paris, France
10:30 - 11:00	Free Papers
10:30 - 10:40	10: Abstract presentation: Side-to-side stricturoplasty and its modification over the ileocecal valve for extensive Crohn's ileitis: Single center long-term outcome G. Bislenghi, Leuven, Belgium
10:40 - 10:50	11: Abstract presentation: ECCO Grant recipient: Preliminary results of the HOT-TOPIC trial (Hyperbaric Oxygen Therapy for the Treatment Of Perianal fistulas In Crohn's Disease) C. Lansdorp, Amsterdam, The Netherlands
10:50 - 11:00	12: Abstract presentation: Platelet-Rich Stroma injection (PRS) as a novel surgical treatment of refractory perianal fistulas in Crohn's Disease: A pilot study J. Arkenbosch, Rotterdam, The Netherlands
11:00 - 11:15	13: Mesentery in IBD surgery: Bad or good? C. Buskens, Amsterdam, The Netherlands
11:15 - 11:30	14: IBD surgery in children: What does it change? J. Davies, Cambridge, United Kingdom
11:30 - 13:00	Lunch break
11:45 - 12:45	S-ECCO IBD Masterclass Lunch Satellite Symposium
13:00 - 15:00	Session 3: Difficult decisions in IBD surgery C. Buskens, Amsterdam, The Netherlands A. Spinelli, Milan, Italy
13:00 - 13:30	Debate 3: 50 shades of ileocecal resection for CD?
13:00 - 13:10	15: To anastomose or to divert? That is the question... P. Kienle, Mannheim, Germany
13:10 - 13:20	16: Side to side, end to end, or what else? How to join the ends! M. Adamina, Winterthur, Switzerland
13:20 - 13:30	Discussion



European
Crohn's and Colitis
Organisation

Free e-Learning subscription



Open to all Healthcare Professionals
not older than 35 or still in training

- Improve your knowledge and enhance your educational experience with e-CCO Learning
- Take advantage of advanced learning opportunities in IBD with one click
- Browse the ECCO e-Library for material as of ECCO'16 onwards
- No ECCO Membership required: An ECCO Account is all you need
- Log-in via the new ECCO Portal for automatic access
- Renewal of the access every year (if eligible)

Scan and visit

www.e-learning.ecco-ibd.eu



13:30 - 14:20	Debate 4: Surgery for IBD outside the box
13:30 - 13:40	17: Appendectomy W. Bemelman, Amsterdam, The Netherlands
13:40 - 13:50	18: Segmental colectomy in Ulcerative Colitis: A European multicentric study A. Frontali, Clichy, France
13:50 - 14:00	19: Ileostomy for Acute Colitis O. Zmora, Tel Aviv, Israel
14:00 - 14:10	20: Koch pouch P. Myrelid, Linköping, Sweden
14:10 - 14:20	Discussion
14:20 - 15:00	Surgical technique video session
14:20 - 14:30	21: Pandora's box: Compilation of complicated situations in laparoscopic CD P. Kotze, Curitiba, Brazil
14:30 - 15:00	Debate: What is the best technique for IPAA?
14:30 - 14:45	22: Transanal IPAA? J. Warusavitarne, Harrow, United Kingdom
14:45 - 15:00	23: Laparoscopic IPAA? Y. Panis, Clichy, France
15:00 - 15:30	Coffee break
15:30 - 16:00	Session 4: The forgotten rectum S. Vermeire, Leuven, Belgium P. Myrelid, Linköping, Sweden
15:30 - 15:45	24: What to do with the rectal stump after subtotal colectomy? M. Block, Gothenburg, Sweden
15:45 - 16:00	25: Diversion proctitis: Keep it or remove it! S. Danese, Milan, Italy
16:00 - 16:45	Session 5: Consultants' corner on challenging cases Chairman 1 and Consultant 1: Y. Panis, Clichy, France Chairman 2 and Consultant 2: P. Kotze, Curitiba, Brazil Consultant 3: A. Armuzzi, Rome, Italy Consultant 4: P. Myrelid, Linköping, Sweden Consultant 5: H. Tulchinsky, Tel Aviv, Israel
16:00 - 16:45	Challenging cases
16:00-16:15	26: Acute Severe Colitis A. Vardanyan, Moscow, Russia
16:15-16:30	27: A recurrent ileal Crohn's Disease A. D'Hoore, Leuven, Belgium
16:30-16:45	28: An indeterminate colitis G. Sica, Rome, Italy
16:45 - 17:00	29: Closing remarks M. Adamina, Winterthur, Switzerland

7th ECCO-ESGAR Ultrasound Workshop – Advanced

Date: Thursday, February 13, 2020
Time: 07:45-11:45
Organisation: EduCom in collaboration with ESGAR
Target audience: Physicians, Radiologists, Surgeons, Paediatricians
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: 3 CME Credits; prerequisite: completion of the online evaluation form.



Thursday, February 13, 2020

*Lehar 4, Ground Level, Reed Messe Wien
(as of January 15, 2020)*

07:45 - 07:55	1: Welcome & Introduction C. Maaser, Lüneburg, Germany J. Rimola, Barcelona, Spain
07:55 - 09:55	Session 1: Assessment of IBD inflammation and fibrosis G. Maconi, Milan, Italy J. Rimola, Barcelona, Spain
07:55 - 08:15	2: Assessing and grading inflammation in Crohn's Disease and Ulcerative Colitis T. Kucharzik, Lüneburg, Germany
08:15 - 08:35	3: Interactive video presentation 1 T. Kucharzik, Lüneburg, Germany
08:35 - 08:55	4: Assessing and grading fibrosis in Crohn's Disease and Ulcerative Colitis – present and future C. Maaser, Lüneburg, Germany
08:55 - 09:15	5: Interactive video presentation 2 C. Maaser, Lüneburg, Germany
09:15 - 09:35	6: Aspects to consider when using intestinal ultrasound in clinical trials K. Novak, Calgary, Canada
09:35 - 09:55	7: Tips and Tricks on how to optimize your IUS image K. Novak, Calgary, Canada
09:55 - 10:15	Coffee break

10:15 - 11:35	Session 2: Assessment of complications in Crohn's Disease T. Kucharzik, Lüneburg, Germany P. Paolantonio, Rome, Italy
10:15 - 10:30	8: Detection of complications in Crohn's Disease – Signs to look for R. Wilkens, Copenhagen, Denmark
10:30 - 10:50	9: Interactive video presentation 3 R. Wilkens, Copenhagen, Denmark
10:50 - 11:05	10: Therapeutic interventions – Tips and Tricks on IUS-guided abscess drainage T. Kucharzik, Lüneburg, Germany
11:05 - 11:20	11: Is it really IBD? Differential diagnosis of the bowel G. Maconi, Milan, Italy
11:20 - 11:35	12: Interactive video presentation 4 G. Maconi, Milan, Italy
11:35 - 11:45	13: Post course test Summary and Closing remarks C. Maaser, Lüneburg, Germany

7th ClinCom Workshop

Date:	Thursday, February 13, 2020
Time:	08:00-11:40
Organisation:	ClinCom
Target audience:	Physicians, Surgeons, Paediatricians, Clinical researchers, Industry
Registration:	ECCO Membership 2020 required. No onsite registration.
CME accreditation:	3 CME Credits; prerequisite: completion of the online evaluation form.

Thursday, February 13, 2020

*Schubert 1-3, Level 1, Reed Messe Wien
(as of January 15, 2020)*

08:00 - 08:05	1: Welcome & Introduction K. Gecse, Amsterdam, The Netherlands
08:05 - 09:45	Session 1: Sequencing and combination of medical IBD treatments L. Beaugerie, Paris, France
08:05 - 08:20	2: Sequencing: Does the order of treatment change the biology of IBD? B. Siegmund, Berlin, Germany
08:20 - 08:40	3: Practical approach to treatment sequencing K. Gecse, Amsterdam, The Netherlands
08:40 - 09:00	4: Concomitant immunomodulators – One size fits all? U. Kopylov, Tel Aviv, Israel
09:00 - 09:20	5: Combination of biologics, and small molecules and biologics J. Rahier, Yvoir, Belgium
09:20 - 09:45	6: Round Table B. Siegmund, Berlin, Germany K. Gecse, Amsterdam, The Netherlands U. Kopylov, Tel Aviv, Israel J. Rahier, Yvoir, Belgium L. Beaugerie, Paris, France
09:45 - 10:15	Coffee break

10:15 - 11:30	Session 2: Overcoming barriers in IIS P. Bossuyt, Bonheiden, Belgium
10:15 - 10:30	7: Overcoming challenges with your ethical committee and GDPR T. Ahmad, Exeter, United Kingdom
10:30 - 10:50	8: Feasibility vs practicality S. Sebastian, Hull, United Kingdom
10:50 - 11:10	9: Funding (Tips and tricks) E. Louis, Liege, Belgium
11:10 - 11:30	10: Round Table T. Ahmad, Exeter, United Kingdom S. Sebastian, Hull, United Kingdom E. Louis, Liege, Belgium P. Bossuyt, Bonheiden, Belgium
11:30 - 11:40	11: Summary & Closing remarks U. Kopylov, Tel Aviv, Israel
12:00 - 13:00	ClinCom Workshop Lunch Satellite Symposium

8th SciCom Workshop: Similarities and differences in the pathogenesis of immune mediated inflammatory disorders

Date: Thursday, February 13, 2020
Time: 08:45-11:45
Organisation: SciCom
Target audience: Basic scientists and interested clinicians
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: 2 CME Credits; prerequisite: completion of the online evaluation form.

Thursday, February 13, 2020

*Schubert 4-5, Level 1, Reed Messe Wien
(as of January 15, 2020)*

08:45 - 10:05	<i>Session 1: Shared pathways – different diseases – similar therapies?</i> S. Ben-Horin, Ramat Gan, Israel M. Scharl, Zurich, Switzerland
08:45 - 08:50	<i>1: Welcome & Introduction</i> M. Scharl, Zurich, Switzerland
08:50 - 09:15	<i>2: Common and distinct pathways in intestinal and non-intestinal immune mediated inflammatory disorders</i> A. Franke, Kiel, Germany
09:15 - 09:40	<i>3: Shared immune repertoires in IBD and PSC</i> T. Karlsen, Oslo, Norway
09:40 - 10:05	<i>4: Immune cell migration in the control of organ-specific disease manifestation</i> A. Kaser, Cambridge, United Kingdom
10:05 - 10:25	<i>Coffee break</i>
10:25 - 11:45	<i>Session 2: Prevention, treatment targets, therapy – Learning from other immune mediated disorders</i> M. Ferrante, Leuven, Belgium S. Zeissig, Dresden, Germany
10:25 - 10:50	<i>5: Disease interception – Learning from other immune mediated diseases</i> J. Colombel, New York, United States
10:50 - 11:15	<i>6: Treatment targets – Learning from rheumatoid arthritis</i> G. Schett, Erlangen, Germany
11:15 - 11:40	<i>7: From disease control to cure? Learning from psoriasis</i> T. Kündig, Zurich, Switzerland
11:40 - 11:45	<i>8: Closing remarks</i> S. Zeissig, Dresden, Germany

7th P-ECCO Educational Course

Date: Thursday, February 13, 2020
Time: 09:00-11:00
Organisation: P-ECCO
Target audience: Paediatricians, Physicians, Surgeons
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: 2 CME Credits; prerequisite: completion of the online evaluation form.

Thursday, February 13, 2020

*Schubert 6, Level 1, Reed Messe Wien
 (as of January 15, 2020)*

09:00 - 11:00	<i>Cutting-edge Contemporary and Controversial CD Care</i> D. Wilson, Edinburgh, United Kingdom
09:00 - 09:05	<i>1: Welcome</i> D. Wilson, Edinburgh, United Kingdom
09:05 - 09:35	<i>2: Cutting-edge dietary therapy</i> J. Van Limbergen, Amsterdam, The Netherlands
09:35 - 10:05	<i>3: Early biological use</i> L. de Ridder, Rotterdam, The Netherlands
10:05 - 10:30	<i>4: What's best for isolated ileocaecal Crohn's Disease – A surgical or a medical approach?</i> D. Wilson, Edinburgh, United Kingdom J. Davies, Cambridge, United Kingdom
10:30 - 11:00	<i>5: Personalised CD care (risk profiling)</i> A. Assa, Petah Tikvah, Israel

5th H-ECCO IBD Masterclass

Date: Thursday-Friday, February 13-14, 2020

Time: Thursday, February 13: 13:15-17:00

Friday, February 14: 08:00-12:00

Organisation: H-ECCO, endorsed by ESP

Target audience: Histopathologists, Clinicians

Registration: ECCO Membership 2020 required.

No onsite registration.

CME accreditation: 6 CME Credits; prerequisite: completion of the online evaluation form.



Thursday, February 13, 2020

Schubert 4-5, Level 1, Reed Messe Wien

(as of January 15, 2020)

13:15 - 13:20	1: Welcome & Introduction R. Feakins, London, United Kingdom
13:20 - 15:00	Session 1: Diagnosis R. Feakins, London, United Kingdom F. Rosini, London, United Kingdom
13:20 - 13:35	2: Do I really need a histopathologist? J. Lindsay, London, United Kingdom
13:35 - 13:55	3: IBD vs non-IBD in biopsies and reporting guidance R. Feakins, London, United Kingdom
13:55 - 14:15	4: Ulcerative Colitis or Crohn's Disease? The pathologist's contribution M. Tripathi, Cambridge, United Kingdom
14:15 - 14:40	5: Appendiceal pathology in IBD and other circumstances R. Riddell, Toronto, Canada
14:40 - 15:00	6: The liver in IBD F. Rosini, London, United Kingdom
15:00 - 15:30	Coffee break
15:30 - 17:00	Session 2: Challenges M. Tripathi, Cambridge, United Kingdom P. Borralho Nunes, Lisbon, Portugal
15:30 - 15:55	7: Pathogenesis, pathology and management of serrated lesions in IBD and non-IBD L. Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France M. Svrcek, Paris, France
15:55 - 16:15	8: Bowel transplant in IBD and other circumstances M. Tripathi, Cambridge, United Kingdom L. Sharkey, Cambridge, United Kingdom
16:15 - 16:30	9: GI dysplasia and reactive atypia: Can we agree and does p53 help? G. de Hertogh, Leuven, Belgium

16:30 - 16:45	10: Examples of atypia – Slide seminar F. Rosini, London, United Kingdom G. de Hertogh, Leuven, Belgium
16:45 - 17:00	11: Dysplasia – Discussion F. Rosini, London, United Kingdom G. de Hertogh, Leuven, Belgium

Friday, February 14, 2020

*Schubert 4-5, Level 1, Reed Messe Wien
(as of January 15, 2020)*

08:00 - 09:45	Session 3: Mimics and associations P. Irving, London, United Kingdom S. Walsh, Dundee, United Kingdom
08:00 - 08:20	12: Clinical mimics of IBD P. Irving, London, United Kingdom
08:20 - 08:40	13: Unusual patterns of IBD R. Feakins, London, United Kingdom
08:40 - 09:00	14: Mass lesions and diverticular disease and their relationship with IBD S. Walsh, Dundee, United Kingdom
09:00 - 09:20	15: Upper GI pathology in IBD – When is it really IBD? M. Tripathi, Cambridge, United Kingdom
09:20 - 09:45	16: IgG4 pathology – Background and its relevance to IBD Y. Zen, London, United Kingdom
09:45 - 10:15	Coffee break
10:15 - 11:55	Session 4: Evolving concepts G. de Hertogh, Leuven, Belgium M. Svrcek, Paris, France
10:15 - 10:30	17: Predictive and prognostic factors in IBD S. Vermeire, London, United Kingdom
10:30 - 10:45	18: IBD drugs, mucosal healing, and pathology scores G. de Hertogh, Leuven, Belgium
10:45 - 11:00	19: Newer IBD drugs and how clinicians assess them M. Ferrante, Leuven, Belgium
11:00 - 11:15	20: Predictive and prognostic factors in IBD – Could pathology help? F. Rosini, London, United Kingdom
11:15 - 11:30	21: Very early onset IBD and the differential diagnosis of paediatric IBD P. Borralho Nunes, Lisbon, Portugal
11:30 - 11:55	22: Hot topics in IBD M. Svrcek, Paris, France
11:55 - 12:00	23: Closing remarks G. de Hertogh, Leuven, Belgium

5th D-ECCO Workshop

Date: Friday, February 14, 2020
Time: 08:15-12:25
Organisation: D-ECCO
Target audience: Dietitians, IBD Nurses, Physicians
Registration: ECCO Membership 2020 required. No onsite registration.
CME accreditation: 3 CME Credits; prerequisite: completion of the online evaluation form.


Friday, February 14, 2020

*Lehar 4, Ground Level, Reed Messe Wien
 (as of January 15, 2020)*

08:15 - 08:20	1: Welcome M. Campmans-Kuijpers, Groningen, The Netherlands
08:20 - 09:30	Session 1: Science, diet and IBD C. Wall, Christchurch, New Zealand L. Godny, Petah Tikva, Israel
08:20 - 08:38	2: Diet, the aryl hydrocarbon receptor and IBD J. Lindsay, London, United Kingdom
08:38 - 08:56	3: Are all fibers created equal? M. Campmans-Kuijpers, Groningen, The Netherlands
08:56 - 09:15	4: Pitfalls in the assessment of diet and dietary patterns K. Gerasimidis, Glasgow, United Kingdom
09:15 - 09:30	5: If studying effects of diet in humans is difficult, what about cell and animal models? Opportunities and challenges E. Wine, Edmonton, Canada
09:30 - 09:50	Coffee break
09:50 - 10:50	Session 2: Practical clinical nutrition in IBD E. Wine, Edmonton, Canada M. Campmans-Kuijpers, Groningen, The Netherlands
09:50 - 10:10	6: Pre-operative nutritional optimization and the outcome of S-ECCO/D-ECCO topical review M. Adamina, Winterthur, Switzerland C. Wall, Christchurch, New Zealand
10:10 - 10:30	7: Dietary management in patients after pouch surgery L. Godny, Petah Tikva, Israel
10:30 - 10:50	8: Case presentation – The patient's perspective D. O'Hanlon, London, United Kingdom
10:50 - 11:10	Coffee break

11:10 - 12:20	Session 3: Panel discussion / interactive session L. de Ridder, Rotterdam, The Netherlands D. O'Hanlon, London, United Kingdom R. Sigall-Boneh, Tel Aviv, Israel C. Wall, Christchurch, New Zealand E. Wine, Edmonton, Canada
11:10 - 11:35	9: Diet in the era of biologics – Do we need diet in the era of biologics? R. Sigall-Boneh, Tel Aviv, Israel L. de Ridder, Rotterdam, The Netherlands
11:35 - 11:45	10: Abstract presentation: Nutritional assessment in Inflammatory Bowel Disease (IBD) – Development of the Groningen IBD Nutritional Questionnaires (GINQ) V. Peters, The Netherlands
11:45 - 11:55	11: Abstract presentation: Impact of oral ferric maltol and IV iron on health-related quality of life in patients with iron deficiency anaemia and Inflammatory Bowel Disease, and relationship with haemoglobin and serum iron S. Howaldt, Hamburg, Germany
11:55 - 12:20	12: Q&A Session and panel discussion
12:20 - 12:25	13: Closing remarks M. Campmans-Kuijpers, Groningen, The Netherlands

Other symposia

 United We Stand	EFCCA Symposium Meeting room: Schubert 4-5, Level 1, Reed Messe Wien
14:00 - 15:00	Digital Health and Data: IBD patients' view and perspectives

MEET THE EXPERTS BEHIND THE CROHN'S DISEASE EXCLUSION DIET

AT BOOTH 42

February 13 – 15, 2020 | ECCO 2020 | Vienna, Austria



Thursday February 13th

14h – 14h30 (Coffee break)

Introduction to diet in Crohn's Disease (CD)

by Mrs Rotem Sigall-Boneh | Wolfson Medical Center, Israel



Friday February 14th

7h30 – 8h30 (Breakfast meeting)

Crohn's Disease Exclusion Diet (CDED) in the management of CD, current evidences and perspectives

by Prof. Arie Levine | Wolfson Medical Center, Israel

BY INVITATION ONLY



Friday February 14th

10h30 – 11h (Coffee break)

**CDED + Partial Enteral Nutrition (PEN)
Clinical case reports part 1**

by Prof. Johan Van Limbergen | Emma Children's Hospital, The Netherlands



Friday February 14th

15h – 15h30 (Coffee break)

CDED + PEN Clinical case reports part 2

by Prof. Eytan Wine | University of Alberta, Canada



Saturday February 15th

10h20 – 10h50 (Coffee break)

CDED + PEN Clinical case reports part 3

by Prof. Arie Levine | Wolfson Medical Center, Israel

Industry sponsored satellite symposia

Industry sponsored satellite symposia organised by pharmaceutical companies are open to all congress participants. The programmes of symposia are not affiliated with ECCO and sponsors hold responsibility for the content of their respective programmes.


Industry sponsored satellite symposia – Scientific programme (as of January 15, 2020)

Thursday, February 13, 2020

abbvie	Satellite Symposium 1a Organiser: AbbVie Meeting room: Plenary Hall, Hall D, Reed Messe Wien
11:00 - 12:00	<i>The Illusion of Remission</i>
11:00 - 11:05	Welcome T. Raine, Cambridge, United Kingdom
11:05 - 11:20	Standard of Care or Caring Standard? Steroids: The key to unlocking quality care in IBD T. Raine, Cambridge, United Kingdom
11:20 - 11:35	Hidden Figures: What is happening outside of your care? I. Dotan, Tel Aviv, Israel
11:35 - 11:50	Holding all the Aces: The evolution of an endpoint - A look into trials from past and present and changing approaches to steroid-free remission M. Silverberg, Toronto, Canada
11:50 - 12:00	Q&A and Closing Remarks All faculty led by T. Raine, Cambridge, United Kingdom



*Research & Development
in Gastroenterology and
Hepatology*



Paid advertisement by Dr. Falk

VISIT US AT BOOTH # 23, HALL C

DR. FALK PHARMA GmbH



Leinenweberstr. 5
79108 Freiburg
Germany

www.dr.falkpharma.com



Satellite Symposium 1b
Organiser: Janssen
Meeting room: Parallel Hall, Hall C,
Reed Messe Wien (Catering provided)

11:00 - 12:00 ***New dimensions in UC: exploring recent data and measures in IBD***

11:00 - 11:05 ***Welcome and introduction***
 S. Vermeire, Leuven, Belgium

11:05 - 11:20 ***UC: new drugs, new targets and better outcomes?***
 A. Armuzzi, Rome, Italy

11:20 - 11:40 ***How good have we become in predicting outcomes?***
 M. Allez, Paris, France

11:40 - 11:55 ***Is it applicable to daily clinical practice?***
 S. Vermeire, Leuven, Belgium

11:55 - 12:00 ***Conclusions and close of meeting***
 S. Vermeire, Leuven, Belgium



Satellite Symposium 1c
Organiser: Celltrion Healthcare
Meeting room: Lehar 1-3, Ground Level,
Reed Messe Wien

11:00 - 12:00 ***Long-term and switching data of subcutaneous infliximab***


11:00 - 11:05 ***Welcome remarks***
 S. Schreiber, Kiel, Germany

11:05 - 11:20 ***Pivotal clinical data of subcutaneous infliximab CT-P13***
 W. Reinisch, Vienna, Austria


11:20 - 11:35 ***Advancement of therapeutic drug monitoring in Inflammatory Bowel Disease***
 N. Vande Casteele, San Diego, United States

11:35 - 11:50 ***Impact of administration route on pharmacokinetics and immunogenicity: Lessons from CT-P13 SC/IV development program***
 S. Ben-Horin, Tel Aviv, Israel

11:50 - 12:00 ***Panel discussion (Q&A)***
 S. Schreiber, Kiel, Germany
 W. Reinisch, Vienna, Austria
 S. Ben-Horin, Tel Aviv, Israel
 N. Vande Casteele, San Diego, United States

	Satellite Symposium 2a Organiser: Takeda Meeting room: Plenary Hall, Hall D, Reed Messe Wien (Catering provided)
18:45 - 19:45	Multilayered remission in IBD: Is it time to be more ambitious? S. Ghosh, Birmingham, United Kingdom
18:45 - 18:50	Introduction S. Ghosh, Birmingham, United Kingdom
18:50 - 19:05	Why target multilayered remission in IBD? S. Ghosh, Birmingham, United Kingdom
19:05 - 19:20	Case study: What does it look like in Ulcerative Colitis? B. Sands, New York, United States
19:20 - 19:35	Case study: What does it look like in Crohn's Disease? J. Colombel, New York, United States
19:35 - 19:45	Panel Discussion/Q&A All

	Satellite Symposium 2b Organiser: Pfizer Meeting room: Parallel Hall, Hall C, Reed Messe Wien
18:45 - 19:45	
18:45 - 18:50	Welcome and Introductions D. Rubin, Chicago, United States
18:50 - 19:05	What Is the Evidence for Tofacitinib in UC? S. Travis, Oxford, United Kingdom
19:05 - 19:20	A Practical Guide to Using Tofacitinib in the Clinic P. Irving, London, United Kingdom
19:20 - 19:35	Tofacitinib: A Real-World Perspective D. Rubin, Chicago, United States
19:35 - 19:40	Panel Discussion with Audience Q&A All faculty members
19:40 - 19:45	Summary and Close D. Rubin, Chicago, United States

	Satellite Symposium 2c Organiser: Biogen and Samsung Bioepis Meeting room: Lehar 1-3, Ground Level, Reed Messe Wien
18:45 - 19:45	Optimizing IBD management – Seizing the Window of Opportunity
18:45 - 18:50	Opening and introduction M. Ferrante, Leuven, Belgium
18:50 - 19:30	Marc Ferrante moderates an interactive discussion with faculty members and audience Early diagnosis of CD and monitoring of intramural damage with bowel ultrasound C. Maaser, Lüneburg, Germany/All Early and effective treatment of IBD with biologics: real-world evidence on biosimilar-to-biosimilar switches F. Cummings, Southampton, United Kingdom/All Remission in an era of more affordable biologics – exit strategy vs sustained treatment approach M. Ferrante, Leuven, Belgium/All Beyond biologics: the role of stem cell therapies R. Ciccocioppo, Verona, Italy
19:30 - 19:45	Closing remarks M. Ferrante, Leuven, Belgium

Friday, February 14, 2020


	Satellite Symposium 3b Organiser: Eli Lilly & Company Meeting room: Parallel Hall, Hall C, Reed Messe Wien (Breakfast provided)
07:15 - 08:15	Getting a Grip on Ulcerative Colitis: The Urgent Patient Need S. Travis, Oxford, United Kingdom
07:15 - 07:20	Welcome and Introduction S. Travis, Oxford, United Kingdom
07:20 - 07:35	Understanding the Full Impact of UC on Patients' Lives S. Travis, Oxford, United Kingdom G. Wakefield, Bicester, United Kingdom
07:35 - 07:50	Quality of Life in UC: The Patients' Perspective L. Dibley, London, United Kingdom
07:50 - 08:00	Bridging the Gap Between Physician Concerns and Patient Needs in UC: The Importance of Effective Communication B. Sands, New York, United States
08:00 - 08:12	Interactive Q&A and Panel Discussion S. Travis, Oxford, United Kingdom and Faculty Panel
08:12 - 08:15	Closing Remarks S. Travis, Oxford, United Kingdom



Therapeutic Drug Monitoring

By providing TDM, clinicians may improve patient treatment strategy, reducing the risk of inadequate treatments, inappropriate dosages, and side effects¹

Promonitor kits can also quantify biosimilar drug levels^{2,3,4,5}



Current portfolio

Promonitor Infliximab

Promonitor anti-Infliximab

Promonitor Adalimumab

Promonitor anti-Adalimumab

Promonitor Etanercept

Promonitor anti-Etanercept

Promonitor Rituximab

Promonitor anti-Rituximab

Promonitor Golimumab

Promonitor anti-Golimumab

Promonitor Vedolizumab

Promonitor anti-Vedolizumab

Promonitor Ustekinumab

Promonitor anti-Ustekinumab

For further information visit us at Stand 36



1. Harbord M et al. *J Crohns Colitis*. 2017;11(7):769-784; 2. Ruiz-Arguello MB, et al. *J Crohns Colitis* 2017. 2016;75:1693-6; 3. Ruiz-Arguello MB, et al. *J Crohns Colitis* 2019;13(1):S265-266; 4. Ruiz-Arguello MB, et al. *J Crohns Colitis* 2019;13(1):S324; 5. GP 2017, SB4, GP 2015, CT-P10. Data on file. Progenika


DRUG MONITORING

©2019 Grifols, S.A. All rights reserved worldwide.
Product registration and availability vary by country.
Ask your local Grifols representative for more information.

GRIFOLS

Grifols International, S.A.
Parc Empresarial Can Sant Joan
Av. de la Generalitat, 152-158
08174 Sant Cugat del Vallès
Barcelona, Spain
Tel: +34 935 710 500

	Satellite Symposium 3c Organiser: Amgen Meeting room: Lehar 1-3, Ground Level, Reed Messe Wien (Breakfast provided)
07:15 - 08:15	Early intervention with anti-TNFs in UC: The missing piece of the puzzle?
07:15 - 07:20	Welcome and introductions F. Cummings, Southampton, United Kingdom
07:20 - 08:10	Interactive debate: Is early intervention with anti-TNFs the key to achieving long-lasting remission in patients with UC? M. Ferrante, Leuven, Belgium G. Fiorino, Rozzano, Italy Moderated by F. Cummings, Southampton, United Kingdom
08:10 - 08:15	Closing remarks F. Cummings, Southampton, United Kingdom
	Satellite Symposium LS1 Organiser: Takeda Meeting room: Plenary Hall, Hall D, Reed Messe Wien (Lunch provided)
12:40 - 13:20	How to sequence advanced therapies in IBD: Evidence from clinical trials and real-world experience S. Schreiber, Kiel, Germany
12:40 - 12:45	Why Sequencing Matters? S. Schreiber, Kiel, Germany
12:45 - 13:20	Which Therapy and When? S. Schreiber, Kiel, Germany B. Bressler, Vancouver, Canada

A cluster of blue puzzle pieces in the top right corner, with one piece showing a red and white pattern.

Early intervention with anti-TNFs in UC: the missing piece of the puzzle?

An Amgen-sponsored satellite symposium
at the 15th Congress of ECCO

Room: Lehar 1-3, Reed Messe Wien

Friday 14 February 2020,

07:15-08:15


An interactive debate

Chaired by: Fraser Cummings, UK

Faculty: Marc Ferrante, Belgium

Gionata Fiorino, Italy


Breakfast will be available before the symposium

A large graphic of puzzle pieces at the bottom of the page. Most are blue, but one central piece is red and white, matching the one in the top right.

This programme is not affiliated with ECCO
Paid advertisement by Amgen Biosimilars

©2020 Amgen Inc. All rights reserved. SC-EU-ABP501-00120 November 2019



	Satellite Symposium LS2 Organiser: Roche Meeting room: Parallel Hall, Hall C, Reed Messe Wien (Lunch provided)
12:40 - 13:20	A Next-Generation, Dual-Action Anti-Integrin Therapy for IBD S. Vermeire, Leuven, Belgium
12:40 - 12:43	Welcome and Objectives S. Vermeire, Leuven, Belgium
12:43 - 12:53	Targeting $\beta 7$: Mechanisms of a Next-Generation, Dual-Action Anti-Integrin Therapy for IBD M. Neurath, Erlangen, Germany
12:53 - 13:00	Leading the Evolution: A Phase 3 Clinical Development Programme S. Vermeire, Leuven, Belgium
13:00 - 13:15	Emerging Horizons: Results from Phase 3 Clinical Studies of a Dual-Action Anti-Integrin Therapy in UC and Crohn's Disease D. Rubin, Chicago, United States
13:15 - 13:20	Closing Remarks S. Vermeire, Leuven, Belgium

 GILEAD Galápagos	Satellite Symposium LS3 Organiser: Gilead Meeting room: Lehar 1-3, Ground Level, Reed Messe Wien (Lunch provided)
12:40 - 13:20	In Darwin's footsteps: Adaption through Innovation in IBD – Insights from Patients and Clinicians
12:40 - 12:50	From simple beginnings: The evolution of IBD management G. D'Haens, Amsterdam, The Netherlands
12:50 - 13:00	Adaption of IBD management: Emerging approaches V. Jairath, London, Canada
13:00 - 13:20	Thriving in a changed environment: Evolution of patient expectations in 2020 and beyond Interactive discussion G. D'Haens, Amsterdam, The Netherlands V. Jairath, London, Canada

Industry sponsored satellite symposia

 TILLOTTS PHARMA <small>2018-2019</small>	Satellite Symposium LS4 Organiser: Tillotts Pharma Meeting room: Strauss 1-2, Ground Level, Reed Messe Wien (Lunch provided)
12:40 - 13:20	<i>Terra Incognita – for explorers in IBD</i>
12:40 - 12:45	<i>Welcome and introduction</i> B. Feagan, London, Canada
12:45 - 13:00	<i>Patient preference: Exploring patient expectations</i> P. Lakatos, Budapest, Hungary; Montreal, Canada
13:00 - 13:20	<i>IBD-U: The patient who seems to not exist</i> R. Russell, Glasgow, United Kingdom J. Burisch, Hvidovre, Denmark
 ARENA <small>PHARMACEUTICALS</small>	Satellite Symposium 4b Organiser: Arena Pharmaceuticals Meeting room: Parallel Hall, Hall C, Reed Messe Wien (Catering provided)
18:40 - 19:40	<i>Hype, hope or reality: Integrating histology into a treat-to-target strategy in Ulcerative Colitis (UC)</i>
18:40 - 18:50	<i>Welcome, introductions and overview of histology scoring systems</i> W. Sandborn, La Jolla, California, United States
18:50 - 19:30	<i>Debate: Should histologic remission be the target of treatment in everyday clinical practice for patients with UC?</i>
18:50 - 19:05	<i>For: Histologic remission should be the target of treatment in everyday clinical practice for patients with UC</i> G. D'Haens, Amsterdam, The Netherlands
19:05 - 19:20	<i>Against: Histologic remission should not be the target of treatment in everyday clinical practice for patients with UC</i> P. Lakatos, Montreal, Québec, Canada
19:20 - 19:25	<i>For: Rebuttal</i> G. D'Haens, Amsterdam, The Netherlands
19:25 - 19:30	<i>Against: Rebuttal</i> P. Lakatos, Montreal, Québec, Canada
19:30 - 19:40	<i>Panel discussion, Q&A and closing remarks</i> All; moderated by W. Sandborn, La Jolla, California, United States



Satellite Symposium 4c
Organiser: Janssen
Meeting room: Lehar 1-3, Ground Level,
Reed Messe Wien (Catering provided)

18:40 - 19:40 20 20 vision in IBD

18:40 - 18:45 **Welcome and introduction**
 S. Ghosh, Birmingham, United Kingdom

18:45 - 18:55 **Targeting the IL-12/23 pathways in IBD**
 R. Atreya, Erlangen, Germany

18:55 - 19:10 **Exploring new frontiers with "STARDUST"**
 A. Dignass, Frankfurt, Germany

19:10 - 19:25 **Sharpening our focus with emerging real-world data**
 S. Ghosh, Birmingham, United Kingdom

19:25 - 19:35 **Interactive conversations**
 Audience and panel

19:35 - 19:40 **Conclusion/what did we learn today?**
 S. Ghosh, Birmingham, United Kingdom

Celgene |
 A Bristol-Myers
 Squibb Company

Satellite Symposium 4d
Organiser: Celgene, a Bristol-Myers Squibb
company
Meeting room: Strauss 1-2, Ground Level,
Reed Messe Wien

18:40 - 19:40 Connecting the dots: Making the invisible visible

18:40 - 18:45 **Welcome and introduction: Setting the scene**
 I. Dotan, Tel Aviv, Israel


18:45 - 19:00 **Sketching the portrait**
 P. Irving, London, United Kingdom

19:00 - 19:15 **What makes a masterpiece?**
 R. Panaccione, Calgary, Canada

19:15 - 19:35 **Adding an innovative touch**
 I. Dotan, Tel Aviv, Israel
 P. Irving, London, United Kingdom
 R. Panaccione, Calgary, Canada

19:35 - 19:40 **Conclusion: Revealing the full picture**
 I. Dotan, Tel Aviv, Israel

Industry sponsored satellite symposia – Educational programme (as of January 15, 2020) **Wednesday, February 12, 2020 – N-ECCO School**

	Satellite Symposium Organiser: Takeda Meeting room: Schubert 1-3, Level 1, Reed Messe Wien (Lunch provided)
12:30 - 13:30	<i>Joining the dots: A connected approach to short bowel syndrome with intestinal failure</i>
12:30 - 12:35	<i>The starting line</i> S. Lal, Salford, United Kingdom
12:35 - 13:25	<i>The twists and turns of short bowel syndrome</i> S. Lal, Salford, United Kingdom C. Cawley, Salford, United Kingdom
13:25 - 13:30	<i>The final dot...</i> S. Lal, Salford, United Kingdom

Thursday, February 13, 2020 – N-ECCO Network Meeting

	Satellite Symposium Organiser: Takeda Meeting room: Strauss 1-2, Ground Level, Reed Messe Wien (Breakfast provided)
08:00 - 08:45	<i>Let's talk about sex!</i>
08:00 - 08:10	<i>Let's get it on!</i> K. Greveson, London, United Kingdom
08:10 - 08:40	<i>Talking sex! – A nurse's guide</i> K. Greveson, London, United Kingdom L. Grover, London, United Kingdom
08:40 - 08:45	<i>Kay's final thoughts</i> K. Greveson, London, United Kingdom

Thursday, February 13, 2020 – S-ECCO IBD Masterclass

	Satellite Symposium Organiser: Takeda Meeting room: Stolz 1-2, Ground Level, Reed Messe Wien (Lunch provided)
11:45 - 12:45	<i>Up close and personal! New approaches to Crohn's perianal fistulas</i>
11:45 - 11:50	<i>Welcome and introductions</i> I. White, Kfar Saba, Israel
11:50 - 12:10	<i>Data: The low down</i> I. White, Kfar Saba, Israel
12:10 - 12:20	<i>Stem cells in action!</i> I. White, Kfar Saba, Israel
12:20 - 12:40	<i>Our patients' stories</i> I. White, Kfar Saba, Israel
12:40 - 12:45	<i>Summary and close</i> I. White, Kfar Saba, Israel

Thursday, February 13, 2020 – ClinCom Workshop



abivax

Satellite Symposium Organiser: Abivax
Meeting room: Schubert 1-3, Level 1,
Reed Messe Wien

12:00 - 13:00	<i>ABX464, a novel anti-inflammatory oral drug candidate based on a new mechanism of action to generate microRNA-124: From bench to bedside</i> W. Sandborn, La Jolla, United States X. Hébuterne, Nice, France
12:00 - 12:05	<i>Welcome and opening remarks</i> W. Sandborn, La Jolla, United States
12:05 - 12:20	<i>The continued need to develop novel drugs in Ulcerative Colitis</i> W. Sandborn, La Jolla, United States
12:20 - 12:35	<i>Mechanism of action and preclinical assessment of ABX464</i> D. Scherrer, Montpellier, France
12:35 - 12:50	<i>Clinical data from the phase 2a induction and maintenance studies with ABX464 in Ulcerative Colitis</i> X. Hébuterne, Nice, France
12:50 - 13:00	<i>Questions and answers</i>

Thursday, February 13, 2020 – N-ECCO Network Meeting

PHARMACOSMOS

Satellite Symposium Organiser: Pharmacosmos
Meeting room: Strauss 1-2, Ground Level,
Reed Messe Wien (Lunch provided)

12:45 - 13:45	<i>CARE, CALM and COMFORT</i> <i>Important factors when treating iron deficiency with IV iron</i>
12:45 - 12:50	<i>Welcome and Introduction</i> A. Hindhede, Nyborg, Denmark
12:50 - 13:10	<i>High dose IV iron therapy in patients with IBD and safety considerations</i> M. Jahnsen, Oslo, Norway
13:10 - 13:30	<i>UK experience in an IBD setting of IV iron – effectiveness, safety and convenience</i> J. Kearns, Antrim, United Kingdom
13:30 - 13:45	<i>Q&A and Closing</i> A. Hindhede, Nyborg, Denmark All faculty

Industry exhibition

Opening hours


Thursday, February 13, 2020	10:30 - 18:00
Friday, February 14, 2020	08:00 - 18:00
Saturday, February 15, 2020	08:00 - 13:00


List of exhibitors & sponsors

Company	Booth number
<i>AbbVie</i>	3
<i>AbbVie</i>	14
<i>Allergan</i>	47
<i>Amgen</i>	40
<i>Arena Pharmaceuticals</i>	43
<i>Biogen</i>	12
<i>Boehringer Ingelheim Pharma</i>	32
<i>Bristol-Myers Squibb</i>	11
<i>Bristol-Myers Squibb</i>	44
<i>Bühlmann Laboratories</i>	6
<i>CALPRO AS</i>	37
<i>Celltrion</i>	38
<i>CTMA</i>	35
<i>Dr. Falk Pharma</i>	23
<i>Edimark (La lettre de l'Hepato-Gastro-entérologie)</i>	45
<i>EFCCA</i>	48
<i>Eli Lilly and Company</i>	8
<i>Ferring International Center S.A.</i>	10
<i>Fresenius Kabi</i>	24
<i>Gilead</i>	13
<i>Gilead</i>	31
<i>Grifols</i>	36

Company	Booth number
<i>IBD Passport</i>	20
<i>Immundiagnostik</i>	19
<i>iThera Medical</i>	26
<i>Janssen</i>	9
<i>Janssen</i>	39
<i>Mendes S.A.</i>	34
<i>Nestle Health Science</i>	42
<i>NIHR Clinical Research Network</i>	21
<i>Nikkiso</i>	18
<i>Norgine</i>	7
<i>Pfizer</i>	15
<i>Pfizer</i>	17
<i>Predictimmune</i>	28
<i>R-Biopharm</i>	27
<i>Robarts Clinical Trials B.V.</i>	33
<i>Roche</i>	5
<i>Shire (now part of Takeda)</i>	42
<i>Takeda</i>	1
<i>Takeda</i>	4
<i>Takeda</i>	16
<i>Theradiag</i>	30
<i>Thermo Fisher Scientific</i>	22
<i>Tillotts</i>	2
<i>UEG United European Gastroenterology GmbH</i>	29
<i>Wisepress</i>	25
<i>Zero Gravity Skin</i>	46

Exhibition Plan





Corporate sponsors

(as of January 15, 2020)

ECCO gratefully acknowledges the support of the following ECCO Corporate Members:

abbvie





Janssen-Sponsored Satellite Symposia at the 15th Congress of ECCO, Vienna, Austria

New dimensions in UC: exploring recent data and measures in IBD

**Thursday 13 February
11:00–12:00
Parallel hall**

**Matthieu Allez (FR)
Alessandro Armuzzi (IT)
Séverine Vermeire (BE)**

20 20 vision in IBD

**Friday 14 February
18:40–19:40
Lehar 1–3**

**Raja Atreya (DE)
Axel Dignass (DE)
Subrata Ghosh (UK)**

Paid advertisement by Janssen.

This programme is not affiliated with ECCO.

With the support of Janssen Pharmaceutical Companies
of Johnson & Johnson in EMEA

Janssen Pharmaceutica NV
Turnhoutseweg 30
B-2340 Beerse, Belgium


Date of preparation: January 2020
EM-25675

janssen  **Immunology**

PHARMACEUTICAL COMPANIES OF 

Inflammatory Bowel Diseases

Announcement 2021



16th Congress of ECCO
Messe Berlin
February 24-27, 2021

Imprint

Publisher

ECCO – European Crohn's and Colitis
Organisation

OCEAiN – Organisation, Congress,
Emotion, Association, iNnovation GmbH
Ungargasse 6/13, 1030 Vienna, Austria

Phone: +43-(0)1-710 22 42

Fax: +43-(0)1-710 22 42-001

E-Mail: ecco-congress@ecco-ibd.eu

Web: www.ecco-ibd.eu



European
Crohn's and Colitis
Organisation



February 12-15, 2020 • Vienna, Austria 75

How does the **JAK-STAT** pathway fuel IBD?



At Gilead and Galapagos, we're investigating more about the JAK-STAT pathway in proinflammatory cytokine signalling and clinical manifestations of inflammatory bowel disease.

Visit us at **Booth 13**, or fuel your knowledge at **[learnJAKSTAT.com](https://www.learnJAKSTAT.com)**



Paid advertisement by Gilead. This programme is not affiliated with ECCO. GILEAD and the GILEAD logo are registered trademarks of Gilead Sciences, Inc., or one of its related companies. GALAPAGOS and the GALAPAGOS logo are registered or pending trademarks of Galapagos NV. © 2019 Gilead Sciences, Inc. All rights reserved.
Date of preparation 01/20. AT-INF-2019-11-0021